No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d1xn2C_, 1.0000, 0.00, 1.000, 389, 389, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
2, d1xn2D_, 0.9989, 0.23, 1.000, 389, 389, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
3, d2g94D_, 0.9984, 0.28, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
4, d1xn3D_, 0.9984, 0.28, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
5, d1xn2A_, 0.9984, 0.29, 1.000, 389, 389, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
6, d1xn2B_, 0.9983, 0.30, 1.000, 389, 389, NEW SUBSTRATE BINDING POCKETS FOR BETA-SECRETASE.
7, d2g94B_, 0.9982, 0.30, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
8, d2g94A_, 0.9981, 0.31, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
9, d1xn3C_, 0.9981, 0.31, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
10, d2qp8B_, 0.9973, 0.39, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH734723
11, d2g94C_, 0.9973, 0.38, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A POTENT AND HIGHLY SELECTIVE INHIBITOR.
12, d3cidB_, 0.9971, 0.39, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH726222
13, d3cicB_, 0.9971, 0.40, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH709583
14, d2qmgB_, 0.9971, 0.39, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH745966
15, d2qmfB_, 0.9971, 0.39, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH735310
16, d2qmdB_, 0.9971, 0.40, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH722924
17, d3cibB_, 0.9970, 0.40, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH727596
18, d2qk5B_, 0.9970, 0.41, 1.000, 389, 389, STRUCTURE OF BACE1 BOUND TO SCH626485
19, d1m4hB_, 0.9970, 0.41, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
20, d3l58B_, 0.9969, 0.41, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH589432
21, d1fknB_, 0.9968, 0.42, 1.000, 389, 389, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
22, d1m4hA_, 0.9963, 0.47, 1.000, 391, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR OM00-3
23, d2zhrA_, 0.9962, 0.49, 0.997, 390, 389, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
24, d2vkmC_, 0.9962, 0.46, 1.000, 389, 389, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
25, d2qmgA_, 0.9961, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH745966
26, d2qmfA_, 0.9961, 0.48, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH735310
27, d2qmdA_, 0.9961, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH722924
28, d3cidA_, 0.9960, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH726222
29, d3cicA_, 0.9960, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH709583
30, d2qp8A_, 0.9960, 0.49, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH734723
31, d3l58A_, 0.9958, 0.50, 1.000, 395, 389, STRUCTURE OF BACE BOUND TO SCH589432
32, d3cibA_, 0.9958, 0.50, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH727596
33, d2vkmD_, 0.9958, 0.47, 1.000, 389, 389, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
34, d2qk5A2, 0.9958, 0.50, 1.000, 393, 389, STRUCTURE OF BACE1 BOUND TO SCH626485
35, d3l5fB_, 0.9957, 0.49, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH736201
36, d3kmxB_, 0.9957, 0.49, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH346572
37, d1xs7D_, 0.9957, 0.49, 1.000, 389, 389, CRYSTAL STRUCTURE OF A CYCLOAMIDE-URETHANE-DERIVED NOVEL INHIBITOR BOUND TO HUMAN BRAIN MEMAPSIN 2 (BETA-SECRETASE).
38, d3kn0B_, 0.9956, 0.50, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH708236
39, d4h3fB_, 0.9955, 0.50, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
40, d1fknA_, 0.9955, 0.53, 1.000, 391, 389, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
41, d1xn3A_, 0.9954, 0.52, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
42, d4djyB_, 0.9952, 0.53, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE
43, d3kmyB_, 0.9952, 0.52, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH12472
44, d2p4jB_, 0.9952, 0.56, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
45, d2p4jC_, 0.9951, 0.57, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
46, d2p4jA_, 0.9951, 0.57, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
47, d1xn3B_, 0.9951, 0.55, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOUND TO A LONG INHIBITOR WITH ADDITIONAL UPSTREAM RESIDUES.
48, d4djxB_, 0.9950, 0.53, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 5-(3-(5-CHLOROPYRIDIN-3-YL)PHENYL)-5- CYCLOPROPYL-2-IMINO-3-METHYLIMIDAZOLIDIN-4-ONE
49, d4h3jB_, 0.9948, 0.54, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE
50, d1sgzA_, 0.9948, 0.55, 1.000, 389, 389, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
51, d2vkmB_, 0.9947, 0.59, 1.000, 389, 389, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
52, d1sgzD_, 0.9947, 0.57, 1.000, 389, 389, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
53, d4h3iB_, 0.9946, 0.55, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(3-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
54, d4h3gB_, 0.9945, 0.55, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE
55, d1sgzB_, 0.9943, 0.58, 1.000, 389, 389, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
56, d2vkmA_, 0.9942, 0.61, 1.000, 389, 389, CRYSTAL STRUCTURE OF GRL-8234 BOUND TO BACE (BETA-SECRETASE)
57, d1sgzC_, 0.9942, 0.58, 1.000, 389, 389, CRYSTAL STRUCTURE OF UNBOUND BETA-SECRETASE CATALYTIC DOMAIN.
58, d4djuB_, 0.9941, 0.60, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-55-DIPHENYLIMIDAZOLIDIN- 4-ONE
59, d3kmxA_, 0.9940, 0.61, 1.000, 395, 389, STRUCTURE OF BACE BOUND TO SCH346572
60, d2p4jD_, 0.9940, 0.62, 1.000, 389, 389, CRYSTAL STRUCTURE OF BETA-SECRETASE BOND TO AN INHIBITOR WITH ISOPHTHALAMIDE DERIVATIVES AT P2-P3
61, d3l5fA_, 0.9939, 0.60, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH736201
62, d3kmyA_, 0.9937, 0.62, 1.000, 395, 389, STRUCTURE OF BACE BOUND TO SCH12472
63, d3l5eA_, 0.9936, 0.62, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH736062
64, d3l59B_, 0.9935, 0.64, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH710413
65, d3l5dB_, 0.9934, 0.65, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO SCH723873
66, d4djuA_, 0.9933, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-55-DIPHENYLIMIDAZOLIDIN- 4-ONE
67, d4fs4A_, 0.9932, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO (S)-4-(3 -METHOXY-[11 -BIPHENYL]-3-YL)-1 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
68, d4djyA_, 0.9932, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO (R)-5-CYCLOPROPYL-2-IMINO-3-METHYL-5-(3-(5- (PROP-1-YN-1-YL)PYRIDIN-3-YL)PHENYL)IMIDAZOLIDIN-4-ONE
69, d4h3fA_, 0.9931, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
70, d4djxA_, 0.9931, 0.64, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 5-(3-(5-CHLOROPYRIDIN-3-YL)PHENYL)-5- CYCLOPROPYL-2-IMINO-3-METHYLIMIDAZOLIDIN-4-ONE
71, d4djwA_, 0.9930, 0.65, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-5-PHENYL-5-(3-(PYRIDIN-3- YL)PHENYL)IMIDAZOLIDIN-4-ONE
72, d3l59A_, 0.9929, 0.66, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO SCH710413
73, d4djwB_, 0.9926, 0.73, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-3-METHYL-5-PHENYL-5-(3-(PYRIDIN-3- YL)PHENYL)IMIDAZOLIDIN-4-ONE
74, d4h3gA_, 0.9924, 0.67, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE
75, d4djvB_, 0.9924, 0.73, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-5-(3 -METHOXY-[11 -BIPHENYL]-3- YL)-3-METHYL-5-PHENYLIMIDAZOLIDIN-4-ONE
76, d4djvA_, 0.9924, 0.70, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-IMINO-5-(3 -METHOXY-[11 -BIPHENYL]-3- YL)-3-METHYL-5-PHENYLIMIDAZOLIDIN-4-ONE
77, d4fs4B_, 0.9922, 0.76, 1.000, 389, 389, STRUCTURE OF BACE BOUND TO (S)-4-(3 -METHOXY-[11 -BIPHENYL]-3-YL)-1 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
78, d4h3jA_, 0.9921, 0.70, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO 2-FLUORO-5-(5-(2-IMINO-3-METHYL-4-OXO-6- PHENYLOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL)THIOPHEN-2-YL) BENZONITRILE
79, d4ha5A_, 0.9920, 0.68, 1.000, 390, 389, STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-14-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE
80, d4gidC_, 0.9916, 0.59, 1.000, 388, 388, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
81, d3l5cB_, 0.9907, 0.49, 0.997, 387, 387, STRUCTURE OF BACE BOUND TO SCH723871
82, d4fslB_, 0.9904, 0.49, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
83, d4fslE_, 0.9900, 0.51, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
84, d4fslA_, 0.9900, 0.51, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
85, d4fslD_, 0.9899, 0.52, 1.000, 387, 387, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-DB-MUT) COMPLEX WITH N-(N-(4- ACETAMIDO-3-CHLORO-5-METHYLBENZYL) CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5-METHYL-4-ISOTHIAZOLECARBOXAMIDE
86, d3lnkB_, 0.9897, 0.37, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH743813
87, d4r91B_, 0.9890, 0.42, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (CYCLOPENTYLAMINO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
88, d4r93B_, 0.9888, 0.43, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-1-METHYL-5-OXO-4- (((1S3R)-3-(3-PHENYLUREIDO)CYCLOHEXYL)METHYL)IMIDAZOLIDIN-2-IMINIUM
89, d4r95A_, 0.9887, 0.44, 1.000, 387, 386, BACE-1 IN COMPLEX WITH 2-(((1R3S)-3-(((R)-4-(2-CYCLOHEXYLETHYL)-2- IMINIO-1-METHYL-5-OXOIMIDAZOLIDIN-4-YL)METHYL)CYCLOHEXYL)AMINO) QUINOLIN-1-IUM
90, d4r91A_, 0.9887, 0.44, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (CYCLOPENTYLAMINO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
91, d4gidA_, 0.9887, 0.62, 1.000, 387, 387, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
92, d4r95B_, 0.9886, 0.45, 1.000, 386, 386, BACE-1 IN COMPLEX WITH 2-(((1R3S)-3-(((R)-4-(2-CYCLOHEXYLETHYL)-2- IMINIO-1-METHYL-5-OXOIMIDAZOLIDIN-4-YL)METHYL)CYCLOHEXYL)AMINO) QUINOLIN-1-IUM
93, d4r93A_, 0.9886, 0.45, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-1-METHYL-5-OXO-4- (((1S3R)-3-(3-PHENYLUREIDO)CYCLOHEXYL)METHYL)IMIDAZOLIDIN-2-IMINIUM
94, d4frsB_, 0.9886, 0.45, 1.000, 387, 386, STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-14-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM
95, d4ha5B_, 0.9884, 0.46, 1.000, 386, 386, STRUCTURE OF BACE BOUND TO (S)-3-(5-(2-IMINO-14-DIMETHYL-6- OXOHEXAHYDROPYRIMIDIN-4-YL)THIOPHEN-3-YL)BENZONITRILE
96, d3lnkA_, 0.9884, 0.48, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH743813
97, d3l5eB_, 0.9884, 0.47, 1.000, 386, 386, STRUCTURE OF BACE BOUND TO SCH736062
98, d4h1eB_, 0.9883, 0.46, 1.000, 387, 386, STRUCTURE OF BACE-1 BOUND TO (7AR)-6-BENZOYL-7A-(4-(3-CYANOPHENYL) THIOPHEN-2-YL)-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN- 2(3H)-IMINIUM
99, d4gidB_, 0.9883, 0.63, 1.000, 387, 387, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
100, d4r8yB_, 0.9882, 0.48, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((R)-1-(2- CYCLOPENTYLACETYL)PYRROLIDIN-3-YL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN- 2-IMINIUM
101, d4gidD_, 0.9882, 0.63, 1.000, 387, 387, STRUCTURE OF BETA-SECRETASE COMPLEXED WITH INHIBITOR
102, d4r92B_, 0.9881, 0.48, 1.000, 386, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (ISONICOTINAMIDO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
103, d3l5bB_, 0.9881, 0.49, 1.000, 386, 386, STRUCTURE OF BACE BOUND TO SCH713601
104, d4r8yA_, 0.9880, 0.49, 1.000, 387, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((R)-1-(2- CYCLOPENTYLACETYL)PYRROLIDIN-3-YL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN- 2-IMINIUM
105, d2zhrB_, 0.9880, 0.30, 1.000, 385, 385, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH OM99-2 AT PH 5.0
106, d4frsA_, 0.9879, 0.49, 1.000, 386, 386, STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-14-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM
107, d4h1eA_, 0.9877, 0.50, 1.000, 386, 386, STRUCTURE OF BACE-1 BOUND TO (7AR)-6-BENZOYL-7A-(4-(3-CYANOPHENYL) THIOPHEN-2-YL)-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN- 2(3H)-IMINIUM
108, d4r92A_, 0.9874, 0.55, 1.000, 388, 386, BACE-1 IN COMPLEX WITH (R)-4-(2-CYCLOHEXYLETHYL)-4-(((1S3R)-3- (ISONICOTINAMIDO)CYCLOHEXYL)METHYL)-1-METHYL-5-OXOIMIDAZOLIDIN-2- IMINIUM
109, d3l5cA_, 0.9872, 0.55, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH723871
110, d3kn0A_, 0.9871, 0.56, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH708236
111, d3l5bA_, 0.9868, 0.58, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO SCH713601
112, d4h3iA_, 0.9862, 0.60, 1.000, 387, 386, STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(3-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[34-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE
113, d2q11B_, 0.9849, 0.89, 0.990, 388, 388, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
114, d3l5dA_, 0.9847, 0.55, 1.000, 386, 385, STRUCTURE OF BACE BOUND TO SCH723873
115, d2q11C_, 0.9827, 0.96, 0.990, 388, 388, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
116, d2q11A_, 0.9827, 0.97, 0.990, 388, 388, STRUCTURE OF BACE COMPLEXED TO COMPOUND 1
117, d3u6aB_, 0.9720, 1.22, 0.990, 386, 385, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
118, d4lc7A1, 0.9718, 1.47, 0.979, 396, 388, AMINOOXAZOLINE INHIBITOR OF BACE-1
119, d4jpeA1, 0.9715, 1.49, 0.979, 396, 388, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
120, d2q15A_, 0.9711, 1.09, 0.990, 385, 385, STRUCTURE OF BACE COMPLEXED TO COMPOUND 3A
121, d4jpcA1, 0.9708, 1.50, 0.979, 396, 388, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
122, d4jp9A1, 0.9697, 1.53, 0.979, 396, 388, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
123, d3u6aC1, 0.9696, 1.53, 0.979, 396, 388, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
124, d4pzxA1, 0.9680, 1.11, 0.995, 383, 383, SYNTHESIS CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS
125, d3qi1A_, 0.9661, 1.39, 0.979, 394, 386, DESIGN AND SYNTHESIS OF HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS: PRIME SIDE CHROMANE-CONTAINING INHIBITORS
126, d5f01A_, 0.9655, 1.06, 0.984, 382, 382, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR2SR)-2-((R)-2-AMINO- 55-DIFLUORO-4-METHYL-56-DIHYDRO-4H-13-OXAZIN-4-YL)-N-(3- CHLOROQUINOLIN-8-YL)CYCLOPROPANECARBOXAMIDE
127, d1ym4A_, 0.9652, 1.20, 0.992, 384, 383, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
128, d3zmgA_, 0.9650, 0.80, 0.995, 379, 379, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
129, d4pzwA1, 0.9647, 1.21, 0.992, 385, 383, SYNTHESIS CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS
130, d3hvgA_, 0.9646, 1.24, 0.984, 391, 383, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
131, d1ym4C_, 0.9643, 0.68, 0.997, 379, 378, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
132, d4lxkB_, 0.9625, 0.81, 0.992, 379, 379, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
133, d3dv1B_, 0.9625, 0.78, 0.995, 378, 378, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
134, d4lxaB_, 0.9624, 0.66, 0.997, 378, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
135, d3udhA1, 0.9621, 0.78, 0.995, 378, 378, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 1
136, d3udyA1, 0.9615, 1.17, 0.984, 388, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 11
137, d3udmA1, 0.9615, 1.18, 0.984, 388, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 8
138, d2f3fB_, 0.9615, 1.19, 0.984, 388, 381, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
139, d2f3eC_, 0.9615, 0.69, 0.997, 377, 377, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
140, d3udrA1, 0.9614, 1.22, 0.995, 381, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14
141, d3udqA1, 0.9614, 1.18, 0.984, 388, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 13
142, d3pi5C_, 0.9613, 1.18, 0.984, 388, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
143, d3udpA1, 0.9612, 1.20, 0.995, 381, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 12
144, d4d8cC_, 0.9611, 1.18, 0.984, 388, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
145, d4wy1A1, 0.9609, 1.22, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 24B
146, d4lxkC_, 0.9609, 1.21, 0.984, 388, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
147, d3udkA1, 0.9609, 1.24, 0.995, 381, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 6
148, d3pi5B_, 0.9609, 1.19, 0.984, 388, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
149, d3dv5C_, 0.9609, 0.73, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
150, d3dv1C_, 0.9609, 1.21, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
151, d2f3eB_, 0.9609, 1.22, 0.995, 381, 381, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
152, d3udnA1, 0.9608, 0.73, 0.997, 377, 377, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 9
153, d3udjA1, 0.9608, 1.20, 0.984, 388, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 5
154, d4j0zA_, 0.9605, 1.21, 0.984, 388, 381, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S5R)-2-AMINO-5-FLUORO-4-FLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
155, d4d8cA_, 0.9605, 1.11, 0.989, 381, 380, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
156, d1ym2B_, 0.9604, 0.74, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
157, d4lxaC_, 0.9603, 0.78, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
158, d4fm8A1, 0.9602, 1.25, 0.995, 381, 381, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 12A
159, d4d83A_, 0.9601, 1.22, 0.984, 388, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
160, d2f3eA_, 0.9600, 0.76, 0.997, 377, 377, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH AXQ093 A MACROCYCLIC INHIBITOR
161, d4d8cB_, 0.9598, 0.77, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
162, d4lxmC_, 0.9597, 0.78, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
163, d4d83B_, 0.9597, 1.26, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
164, d3pi5A_, 0.9597, 0.78, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH BFG356
165, d4fm7A1, 0.9594, 0.78, 0.997, 377, 377, CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14G
166, d3k5fB_, 0.9594, 1.25, 0.984, 388, 381, HUMAN BACE-1 COMPLEX WITH AYH011
167, d4lxmB_, 0.9592, 0.80, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
168, d3k5gC_, 0.9592, 0.81, 0.997, 377, 377, HUMAN BACE-1 COMPLEX WITH BJC060
169, d3k5cB_, 0.9592, 1.27, 0.995, 381, 381, HUMAN BACE-1 COMPLEX WITH NB-216
170, d3dv1A_, 0.9592, 0.80, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-ARV999
171, d3ckpA_, 0.9592, 0.80, 0.997, 377, 377, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
172, d4j0tA_, 0.9589, 0.68, 0.992, 379, 376, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-ETHOXY-PYRIDINE-2- CARBOXYLIC ACID [3-((R)-2-AMINO-55-DIFLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
173, d4lxmA_, 0.9588, 1.15, 0.989, 381, 380, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 12A
174, d3k5dC_, 0.9586, 0.81, 0.997, 377, 377, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
175, d3ckrA_, 0.9584, 0.57, 1.000, 376, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
176, d2oahA_, 0.9584, 0.71, 0.992, 379, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
177, d3k5gB_, 0.9583, 0.72, 0.995, 378, 376, HUMAN BACE-1 COMPLEX WITH BJC060
178, d3k5cA_, 0.9582, 0.83, 0.997, 377, 377, HUMAN BACE-1 COMPLEX WITH NB-216
179, d1ym4B_, 0.9582, 0.84, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AMK640
180, d1ym2A_, 0.9582, 0.85, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
181, d3qbhB_, 0.9581, 0.73, 1.000, 376, 376, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
182, d3k5dA_, 0.9581, 0.74, 0.997, 376, 376, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
183, d3k5cC_, 0.9581, 0.60, 1.000, 375, 375, HUMAN BACE-1 COMPLEX WITH NB-216
184, d2ntrA_, 0.9580, 1.30, 0.995, 381, 381, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO INHIBITOR
185, d3dv5B_, 0.9579, 0.88, 0.992, 379, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
186, d2f3fC_, 0.9579, 0.86, 0.997, 377, 377, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
187, d3dv5A_, 0.9578, 0.84, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-BAV544
188, d4lxaA_, 0.9575, 0.85, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11A
189, d2f3fA_, 0.9575, 0.76, 0.997, 376, 376, CRYSTAL STRUCTURE OF THE BACE COMPLEX WITH BDF488 A MACROCYCLIC INHIBITOR
190, d5t1uA_, 0.9574, 0.62, 1.000, 375, 375, AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY
191, d3k5gA_, 0.9574, 1.18, 0.992, 380, 380, HUMAN BACE-1 COMPLEX WITH BJC060
192, d4lxkA_, 0.9573, 0.86, 0.997, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH COMPOUND 11D
193, d3qbhA_, 0.9573, 0.77, 0.997, 376, 376, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
194, d4n00A1, 0.9567, 0.64, 1.000, 375, 375, DISCOVERY OF 7-THP CHROMANS: BACE1 INHIBITORS THAT REDUCE A-BETA IN THE CNS
195, d4rrsA1, 0.9566, 1.25, 0.984, 387, 380, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
196, d4rrnA1, 0.9565, 1.26, 0.984, 387, 380, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
197, d1ym2C_, 0.9562, 1.27, 0.984, 387, 380, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH NVP-AUR200
198, d4gmiA_, 0.9561, 0.80, 1.000, 376, 376, BACE-1 IN COMPLEX WITH HEA-TYPE MACROCYCLIC INHIBITOR MV078571
199, d2wjoA_, 0.9561, 1.15, 0.992, 380, 379, HUMAN BACE (BETA SECRETASE) IN COMPLEX WITH CYCLOHEXANECARBOXYLIC ACID (2-(2-AM INO-6-PHENOXY-4H- QUINAZOLIN-3-YL)-2-CYCLOHEXYL-ETHYL)-AMIDE
200, d4rroA1, 0.9560, 1.02, 0.989, 380, 378, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
201, d3k5fC_, 0.9560, 1.27, 0.984, 387, 380, HUMAN BACE-1 COMPLEX WITH AYH011
202, d4j0yA_, 0.9559, 0.93, 0.997, 377, 377, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5S)-2-AMINO-5-FLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
203, d2is0A_, 0.9559, 1.10, 0.995, 379, 378, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
204, d2irzA_, 0.9557, 0.98, 0.995, 379, 377, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH INHIBITOR
205, d4r5nA1, 0.9556, 0.99, 0.995, 379, 377, 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
206, d4j17A_, 0.9556, 1.30, 0.984, 387, 380, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-DIFLUOROMETHYL-56-DIHYDRO-4H-[1 3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
207, d4j0vA_, 0.9556, 1.09, 0.995, 379, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R)-2-AMINO-5-FLUORO-4-METHYL-56-DIHYDRO-4H- [13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
208, d4j1eA_, 0.9555, 1.11, 0.995, 379, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6S)-2-AMINO-4-FLUOROMETHYL-6-TRIFLUOROMETHYL- 56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
209, d4i0fA1, 0.9555, 1.10, 0.995, 379, 378, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
210, d4d83C_, 0.9555, 1.16, 0.992, 386, 379, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT
211, d3ivhA_, 0.9555, 0.94, 0.997, 377, 377, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
212, d3ckpC_, 0.9551, 1.14, 0.981, 379, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
213, d2b8lA_, 0.9551, 0.75, 0.992, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
214, d2zjmA_, 0.9548, 1.01, 0.989, 379, 377, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(4-SULFAMOYL-PHENOXY)-ACETAMIDE
215, d3k5dB_, 0.9547, 0.98, 0.995, 377, 377, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH AHM178
216, d3ckrC_, 0.9547, 0.76, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
217, d4i11A1, 0.9544, 0.76, 0.989, 377, 375, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES.
218, d4i0eA1, 0.9544, 1.46, 0.982, 390, 382, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
219, d2qzkA_, 0.9544, 1.10, 0.992, 386, 378, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH I21
220, d2p8hA_, 0.9544, 0.92, 0.995, 376, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
221, d3tpjA_, 0.9540, 1.05, 0.989, 379, 377, APO STRUCTURE OF BACE1
222, d3veuA_, 0.9536, 0.81, 0.987, 377, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-AVI326
223, d3qbhC_, 0.9536, 1.26, 1.000, 380, 379, STRUCTURE BASED DESIGN SYNTHESIS AND SAR OF CYCLIC HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
224, d5ezzA_, 0.9534, 0.81, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-CHLORO-3- PYRIDYL)PHENYL]-4-[4-(DIFLUOROMETHOXY)-3-METHYL-PHENYL]-5H-OXAZOL-2- AMINE
225, d4hztA1, 0.9534, 1.22, 0.995, 379, 378, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
226, d4exgA_, 0.9528, 1.12, 0.992, 386, 378, DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
227, d3ckrB_, 0.9527, 1.08, 0.992, 377, 377, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
228, d3iviA_, 0.9525, 0.96, 0.997, 377, 376, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
229, d4i0hA_, 0.9518, 1.41, 0.992, 380, 379, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
230, d4ewoA_, 0.9518, 0.80, 0.995, 374, 374, DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS
231, d3i25C_, 0.9518, 1.11, 0.995, 377, 377, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
232, d4i10A1, 0.9517, 0.69, 0.992, 373, 373, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
233, d4i0gA1, 0.9517, 1.10, 0.992, 384, 377, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
234, d4j0pA_, 0.9516, 1.19, 0.992, 386, 378, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-4-METHYL-56-DIHYDRO-4H-[13]OXAZIN- 4-YL)-4-FLUORO-PHENYL]-AMIDE
235, d3ckpB_, 0.9516, 0.89, 0.992, 376, 375, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR
236, d2fdpC_, 0.9516, 0.92, 0.997, 376, 375, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
237, d4j1fA_, 0.9513, 0.81, 0.997, 374, 374, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6S)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
238, d3u6aA_, 0.9513, 0.90, 0.987, 376, 375, RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS
239, d4i0zA1, 0.9511, 0.81, 0.995, 374, 374, STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES
240, d3n4lA_, 0.9511, 1.11, 0.992, 384, 377, BACE-1 IN COMPLEX WITH ELN380842
241, d5i3wA_, 0.9509, 0.81, 0.997, 375, 374, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE INHIBITOR 2
242, d1w51A_, 0.9508, 1.09, 0.995, 377, 376, BACE (BETA SECRETASE) IN COMPLEX WITH A NANOMOLAR NON- PEPTIDIC INHIBITOR
243, d4d85A_, 0.9507, 0.81, 0.987, 374, 374, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BVI151
244, d3iviB_, 0.9504, 0.81, 0.995, 374, 374, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
245, d4fcoA_, 0.9501, 1.40, 0.995, 378, 377, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
246, d3msjC_, 0.9501, 0.90, 0.989, 374, 374, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
247, d2ohuA_, 0.9501, 0.86, 0.997, 375, 374, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B
248, d2qzlA_, 0.9500, 1.21, 0.995, 377, 377, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH IXS
249, d4i0iB_, 0.9498, 0.91, 0.989, 375, 374, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
250, d3nshB_, 0.9498, 1.16, 0.992, 376, 375, BACE-1 IN COMPLEX WITH ELN475957
251, d2ohkA_, 0.9498, 1.16, 0.992, 376, 375, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1- AMINO-ISOQUINOLINE
252, d3n4lB_, 0.9496, 1.17, 0.995, 377, 377, BACE-1 IN COMPLEX WITH ELN380842
253, d3ixjA_, 0.9496, 0.77, 0.995, 375, 373, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
254, d2va5A_, 0.9495, 0.80, 0.997, 373, 373, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C
255, d3r1gB1, 0.9494, 1.21, 0.995, 377, 377, STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE- BINDING ANTIBODY
256, d3i25A_, 0.9494, 1.20, 0.981, 380, 378, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
257, d2ohmA_, 0.9494, 0.80, 0.997, 373, 373, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH N~3~-BENZYLPYRIDINE-23-DIAMINE
258, d3tppA_, 0.9493, 1.22, 0.995, 377, 377, CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR
259, d3n4lC_, 0.9493, 0.93, 0.989, 375, 374, BACE-1 IN COMPLEX WITH ELN380842
260, d3msjA_, 0.9493, 0.96, 0.995, 375, 375, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
261, d2ohlA_, 0.9492, 0.79, 0.997, 373, 373, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2- AMINOQUINOLINE
262, d5ezxA_, 0.9490, 1.22, 0.995, 377, 377, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH {(1R2R)-2-[(R)-2-AMINO-4- (4-DIFLUOROMETHOXY-PHENYL)-45-DIHYDRO-OXAZOL-4-YL]-CYCLOPROPYL}-(5- CHLORO-PYRIDIN-3-YL)-METHANONE
263, d4ivtA_, 0.9490, 0.79, 0.989, 374, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
264, d3hw1C_, 0.9490, 0.80, 0.992, 375, 373, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
265, d2iqgA_, 0.9490, 0.90, 0.992, 375, 374, CRYSTAL STRUCTURE OF HYDROXYETHYL SECONDARY AMINE-BASED PEPTIDOMIMETIC INHIBITOR OF HUMAN BETA-SECRETASE (BACE)
266, d2hm1A_, 0.9490, 0.99, 0.987, 375, 374, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR (2)
267, d4i0hB_, 0.9489, 0.98, 0.987, 375, 374, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
268, d3ixkA_, 0.9489, 1.03, 0.995, 375, 374, POTENT BETA-SECRETASE 1 INHIBITOR
269, d4ivsA_, 0.9488, 0.83, 0.997, 373, 373, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
270, d3duyC_, 0.9488, 0.80, 0.992, 373, 373, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
271, d5clmA_, 0.9485, 0.92, 0.997, 374, 374, 14-OXAZINE BACE1 INHIBITORS
272, d2ohqA_, 0.9485, 1.09, 0.989, 376, 376, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4
273, d3uquA_, 0.9484, 1.23, 0.995, 377, 377, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
274, d4xxsA_, 0.9483, 0.88, 0.992, 374, 373, CRYSTAL STRUCTURE OF BACE1 WITH A PYRAZOLE-SUBSTITUTED TETRAHYDROPYRAN THIOAMIDINE
275, d2va6A_, 0.9482, 0.83, 0.992, 376, 373, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 24
276, d3uqxA_, 0.9481, 1.16, 0.995, 376, 376, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
277, d3s2oA_, 0.9481, 0.90, 0.992, 375, 373, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
278, d3msmA_, 0.9481, 1.24, 0.995, 377, 377,  
279, d4i0jA1, 0.9480, 1.24, 0.995, 377, 377, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
280, d3exoA_, 0.9480, 0.86, 0.992, 381, 373, CRYSTAL STRUCTURE OF BACE1 BOUND TO INHIBITOR
281, d1w50A_, 0.9480, 0.84, 0.989, 373, 373, APO STRUCTURE OF BACE (BETA SECRETASE)
282, d2ohrA_, 0.9479, 1.24, 0.995, 377, 377, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6A
283, d3k5fA_, 0.9478, 1.18, 0.995, 377, 377, HUMAN BACE-1 COMPLEX WITH AYH011
284, d2ohnA_, 0.9476, 0.87, 0.995, 373, 373, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4- (4-FLUOROBENZYL)PIPERIDINE
285, d4dpfA_, 0.9475, 1.26, 0.995, 377, 377, BACE-1 IN COMPLEX WITH A HEA-MACROCYCLIC TYPE INHIBITOR
286, d4ke0A_, 0.9474, 1.08, 1.000, 375, 375, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
287, d2p83B1, 0.9474, 1.03, 0.995, 375, 373, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
288, d4ke0C_, 0.9472, 0.65, 0.995, 371, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
289, d3mskA_, 0.9472, 0.67, 0.997, 372, 371, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
290, d3iviC_, 0.9472, 1.25, 0.995, 377, 377, DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS
291, d2hizB1, 0.9472, 0.77, 0.997, 373, 372, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
292, d3ixjC_, 0.9471, 0.65, 0.995, 371, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
293, d4k8sA_, 0.9469, 0.71, 0.997, 371, 371, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
294, d3vf3A_, 0.9469, 0.68, 0.997, 371, 371, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BQQ711
295, d2of0A_, 0.9469, 1.10, 1.000, 375, 375, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5
296, d4di2B_, 0.9468, 1.28, 0.995, 377, 377, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
297, d4d88A_, 0.9468, 1.05, 0.995, 375, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXQ490
298, d3uflA_, 0.9468, 1.10, 1.000, 375, 375, DISCOVERY OF PYRROLIDINE-BASED B-SECRETASE INHIBITORS: LEAD ADVANCEMENT THROUGH CONFORMATIONAL DESIGN FOR MAINTENANCE OF LIGAND BINDING EFFICIENCY
299, d2ohtA_, 0.9468, 0.89, 0.995, 373, 373, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7
300, d4ke0B_, 0.9467, 1.30, 0.995, 377, 377, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13
301, d4wy6A_, 0.9465, 0.97, 0.995, 374, 374, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 36
302, d3ixkC_, 0.9463, 0.89, 0.992, 373, 373, POTENT BETA-SECRETASE 1 INHIBITOR
303, d3hvgC_, 0.9463, 0.74, 0.997, 371, 371, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
304, d2zjjA_, 0.9463, 0.79, 0.997, 373, 372, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)- AMIDE
305, d4i0iA_, 0.9462, 0.54, 0.992, 370, 370, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
306, d3nshA_, 0.9462, 0.82, 0.997, 372, 372, BACE-1 IN COMPLEX WITH ELN475957
307, d3hvgB_, 0.9461, 0.82, 0.997, 372, 372, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0
308, d2hizA1, 0.9461, 0.55, 1.000, 370, 370, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
309, d3ixjB_, 0.9460, 0.69, 0.997, 371, 371, CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR
310, d2wf2A_, 0.9460, 0.92, 0.997, 373, 373, HUMAN BACE-1 IN COMPLEX WITH 8-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3478-TETRAHYDRO-1H6H-(125) THIADIAZEPINO(543-DE)QUINOXALINE-10-CARBOXAMIDE 22- DIOXIDE
311, d2wf1A_, 0.9460, 1.04, 0.987, 374, 374, HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-34-DIHYDRO-1H-(125)THIADIAZEPINO(345- HI)INDOLE-9-CARBOXAMIDE 22-DIOXIDE
312, d2p83A1, 0.9460, 1.03, 0.987, 374, 374, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
313, d3h0bC_, 0.9459, 0.70, 0.997, 371, 371, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
314, d2ohpA_, 0.9458, 0.95, 0.997, 373, 373, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3
315, d3h0bB_, 0.9457, 1.32, 0.995, 377, 377, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
316, d2va7A_, 0.9457, 0.96, 0.997, 373, 373, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 27
317, d2vnnA_, 0.9456, 1.07, 1.000, 374, 374, HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-34-DIHYDRO-1H-(125)THIADIAZEPINO(345- HI)INDOLE-9-CARBOXAMIDE 22-DIOXIDE
318, d4l7jA_, 0.9455, 1.05, 0.987, 374, 374, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE-1)
319, d4frjA_, 0.9455, 1.00, 0.987, 374, 373, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 9L
320, d2wf3A_, 0.9455, 0.93, 0.989, 373, 373, HUMAN BACE-1 IN COMPLEX WITH 6-(ETHYLAMINO)-N-((1S2R)-2- HYDROXY-3-(((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-( PHENYLMETHYL)PROPYL)-1-METHYL-1345-TETRAHYDRO-21- BENZOTHIAZEPINE-8-CARBOXAMIDE 22-DIOXIDE
321, d2vnmA_, 0.9455, 1.05, 0.987, 374, 374, HUMAN BACE-1 IN COMPLEX WITH 3-(11-DIOXIDOTETRAHYDRO-2H-1 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE
322, d4di2A_, 0.9454, 1.06, 0.987, 374, 374, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
323, d3ixkB_, 0.9454, 0.85, 0.995, 375, 372, POTENT BETA-SECRETASE 1 INHIBITOR
324, d4i0iC_, 0.9453, 0.93, 0.997, 373, 373, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS
325, d3nshC_, 0.9453, 1.41, 0.989, 376, 376, BACE-1 IN COMPLEX WITH ELN475957
326, d3i25B_, 0.9453, 1.41, 0.989, 376, 376, POTENT BETA-SECRETASE 1 HYDROXYETHYLENE INHIBITOR
327, d2hizC1, 0.9453, 0.94, 0.992, 373, 373, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE (BACE) IN THE PRESENCE OF AN INHIBITOR
328, d4k8sB_, 0.9452, 0.83, 0.995, 372, 372, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
329, d2p83C1, 0.9452, 0.75, 0.997, 371, 371, POTENT AND SELECTIVE ISOPHTHALAMIDE S2 HYDROXYETHYLAMINE INHIBITOR OF BACE1
330, d2fdpA_, 0.9452, 0.84, 0.995, 372, 372, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
331, d1tqfA_, 0.9452, 0.95, 0.997, 373, 373, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
332, d4d89A_, 0.9450, 0.76, 0.995, 371, 371, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552 DERIVED FROM A SOAKING EXPERIMENT
333, d4b77A_, 0.9450, 1.19, 1.000, 375, 375, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
334, d3vg1A_, 0.9450, 1.17, 1.000, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436 DERIVED FROM A SOAKING EXPERIMENT
335, d2ph6A_, 0.9448, 1.29, 1.000, 376, 376, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
336, d3msjB_, 0.9445, 0.79, 0.992, 371, 371, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR
337, d3hw1B_, 0.9445, 0.88, 0.997, 373, 372, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
338, d3duyB_, 0.9444, 0.66, 0.997, 371, 370, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
339, d4k9hA_, 0.9443, 0.68, 0.997, 370, 370, BACE-1 INHIBITOR COMPLEX
340, d5t1wA_, 0.9442, 0.67, 0.997, 370, 370, AMINOMETHYL-DERIVED BETA SECRETASE (BACE1) INHIBITORS: ENGAGING GLY230 WITHOUT AN ANILIDE FUNCTIONALITY
341, d4l7hA_, 0.9442, 0.77, 0.997, 371, 371, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE-1)
342, d4b72A_, 0.9442, 1.05, 0.987, 374, 373, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
343, d2b8vA_, 0.9442, 1.20, 1.000, 376, 375, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE COMPLEXED WITH L- L000430469
344, d3hw1A_, 0.9440, 0.83, 0.995, 373, 371, STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH LIGAND EV2
345, d4di2C_, 0.9439, 0.66, 1.000, 370, 370, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37
346, d2ohsA_, 0.9439, 0.71, 0.997, 371, 370, X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 6B
347, d4b00A_, 0.9438, 1.08, 1.000, 374, 374, DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND (R)-41)
348, d2vijA_, 0.9437, 1.13, 1.000, 375, 374, HUMAN BACE-1 IN COMPLEX WITH 3-(11-DIOXIDOTETRAHYDRO-2H-1 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(1234-TETRAHYDRO-1-NAPHTHALENYLAMINO) PROPYL)BENZAMIDE
349, d3duyA_, 0.9436, 1.03, 0.989, 373, 373, CRYSTAL STRUCTURE OF HUMAN BETA-SECRETASE IN COMPLEX WITH NVP-AFJ144
350, d2zjkA_, 0.9436, 0.71, 0.997, 370, 370, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
351, d4i0dA1, 0.9435, 0.68, 0.997, 371, 370, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
352, d4dpiA_, 0.9435, 0.99, 1.000, 380, 373, BACE-1 IN COMPLEX WITH HEA-MACROCYCLIC INHIBITOR MV078512
353, d2zjkC_, 0.9435, 1.05, 1.000, 373, 373, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
354, d2vieA_, 0.9435, 0.69, 0.997, 371, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-1-BENZYL-2-HYDROXY- 3-((115-TRIMETHYLHEXYL)AMINO)PROPYL)-3-(ETHYLAMINO)-5-(2- OXOPYRROLIDIN-1-YL)BENZAMIDE
355, d4wtuA_, 0.9434, 1.05, 0.989, 373, 373, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 3-AZA-4- FLUORO-XANTHENE INHIBITOR 22
356, d4bfdA_, 0.9432, 0.80, 0.995, 371, 371, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
357, d4zpfA_, 0.9431, 0.82, 0.995, 372, 371, BACE1 IN COMPLEX WITH 8-(3-((1-AMINOPROPAN-2-YL)OXY)BENZYL)-4- (CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-138-TRIAZASPIRO[4.5]DEC-3-EN- 2-ONE
358, d4x2lA_, 0.9430, 0.84, 0.989, 371, 371, CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 6
359, d4azyA_, 0.9430, 0.82, 0.997, 371, 371, DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND 10)
360, d2xfjA_, 0.9429, 1.15, 1.000, 375, 374, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE
361, d4b1dA_, 0.9427, 1.05, 0.987, 373, 373, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
362, d3uqwA_, 0.9426, 1.25, 1.000, 376, 375, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
363, d4i0hC_, 0.9424, 1.05, 0.992, 375, 373, SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS.
364, d4friA_, 0.9423, 1.25, 0.992, 374, 374, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH BIARYLSPIRO AMINOOXAZOLINE 2 6
365, d5uyuA_, 0.9421, 0.86, 0.995, 372, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE-3- AZAXANTHENE COMPOUND 12
366, d3rsxA_, 0.9421, 0.75, 0.995, 370, 370, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(THIOPHEN-3- YL)QUINOLIN-2-AMINE
367, d4b1eA_, 0.9418, 1.27, 0.992, 375, 375, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
368, d2xfiA_, 0.9418, 1.19, 1.000, 375, 374, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE
369, d2viyA_, 0.9418, 1.01, 0.989, 372, 372, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE
370, d5tolA_, 0.9416, 1.01, 0.989, 372, 372, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 COMPLEXED WITH N- (3-((4AS7AS)-2-AMINO-44A56-TETRAHYDRO-7AH-FURO[23-D][1 3]THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-BROMO-2-PYRIDINECARBOXAMIDE
371, d3mslA_, 0.9416, 1.16, 0.997, 374, 373, FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS
372, d4b1cA_, 0.9415, 1.36, 0.992, 377, 377, NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN
373, d3h0bA_, 0.9415, 1.01, 0.997, 375, 372, DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS
374, d2fdpB_, 0.9415, 1.01, 0.997, 372, 372, CRYSTAL STRUCTURE OF BETA-SECRETASE COMPLEXED WITH AN AMINO- ETHYLENE INHIBITOR
375, d4l7gA_, 0.9414, 0.70, 0.997, 369, 369, DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE1)
376, d2zjkB_, 0.9410, 1.13, 0.971, 373, 373, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(4-FLUORO-BENZYL)-PIPERAZINE-2-CARBOXYLIC ACID(3-MERCAPTO-PROPYL)-AMIDE
377, d4j1cA_, 0.9409, 0.69, 0.997, 369, 369, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-55-DIFLUORO-4-FLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
378, d2wf4A_, 0.9409, 0.81, 0.995, 371, 370, HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO- 1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)- 1346-TETRAHYDRO(12)THIAZEPINO(543-CD)INDOLE-8- CARBOXAMIDE 22-DIOXIDE
379, d4j1iA_, 0.9408, 1.04, 0.989, 372, 372, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R6R)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE
380, d4acuA_, 0.9408, 0.82, 0.995, 371, 370, AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 14
381, d2wezA_, 0.9408, 0.96, 0.997, 372, 371, HUMAN BACE-1 IN COMPLEX WITH 1-ETHYL-N-((1S2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL)METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-4-(2-OXO-1-PYRROLIDINYL)-1H-INDOLE-6-CARBOXAMIDE
382, d2wf0A_, 0.9407, 1.04, 0.989, 372, 372, HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE
383, d4bekA_, 0.9406, 1.04, 0.989, 372, 372, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
384, d4k8sC_, 0.9405, 0.82, 0.995, 371, 370, HYDROXYETHYLAMINE-BASED INHIBITORS OF BACE1: P1-P3 MACROCYCLIZATION CAN IMPROVE POTENCY SELECTIVITY AND CELL ACTIVITY
385, d3zovA_, 0.9405, 0.92, 0.997, 371, 371, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND
386, d4k9hB_, 0.9404, 0.82, 0.995, 371, 370, BACE-1 INHIBITOR COMPLEX
387, d2xfkA_, 0.9404, 0.75, 1.000, 369, 369, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-((METHYLSULFONYL)( PHENYL)AMINO)BENZAMIDE
388, d5f00A_, 0.9398, 0.98, 0.992, 371, 371, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-[3-[(3-CHLORO-8- QUINOLYL)AMINO]PHENYL]-5-METHYL-26-DIHYDRO-14-OXAZIN-3-AMINE
389, d3rthA_, 0.9396, 0.85, 0.995, 371, 370, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(2-(33- DIMETHYLBUT-1-YNYL)PHENYL)QUINOLIN-2-AMINE
390, d4b70A_, 0.9393, 0.97, 0.995, 371, 371, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
391, d4rcfA_, 0.9390, 1.09, 1.000, 372, 372, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 4- FLUOROXANTHENE INHIBITOR 49
392, d2vj9A_, 0.9388, 0.79, 0.992, 370, 369, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(CYCLOHEXYLAMINO)- 2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO- 1-PYRROLIDINYL)BENZAMIDE
393, d2vizA_, 0.9388, 0.92, 0.992, 374, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE
394, d4zpeA_, 0.9387, 0.93, 0.992, 370, 370, BACE1 IN COMPLEX WITH 4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)-8-(3- ISOPROPOXYBENZYL)-138-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE
395, d3dm6B_, 0.9386, 0.81, 0.992, 369, 369, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
396, d4zpgA_, 0.9383, 0.71, 0.997, 368, 368, BACE1 IN COMPLEX WITH 8-BENZYL-4-(CYCLOHEXYLAMINO)-1-(3-FLUOROPHENYL)- 7-METHYL-138-TRIAZASPIRO[4.5]DEC-3-EN-2-ONE
397, d4k9hC_, 0.9383, 0.82, 0.989, 369, 369, BACE-1 INHIBITOR COMPLEX
398, d4acxA_, 0.9383, 0.91, 0.997, 370, 370, AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 23
399, d2vj7A_, 0.9381, 0.91, 0.997, 370, 370, HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S2R)-2- HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE
400, d2vj6A_, 0.9381, 0.95, 0.992, 370, 370, HUMAN BACE-1 IN COMPLEX WITH N-((1S2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE
401, d4frkA_, 0.9375, 0.95, 0.992, 370, 370, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 11A
402, d3dm6A_, 0.9375, 0.83, 0.995, 369, 369, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
403, d2zjiA_, 0.9373, 0.88, 0.997, 369, 369, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(26-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE
404, d4j1hA_, 0.9369, 0.86, 0.992, 370, 369, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S6R)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-56- DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE
405, d4b78A_, 0.9369, 0.88, 0.995, 370, 369, AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN
406, d4b0qA_, 0.9367, 1.19, 1.000, 372, 372, LEAD GENERATION OF BACE1 INHIBITORS BY COUPLING NON-AMIDINE NEW WARHEADS TO A KNOWN BINDING SCAFFOLD
407, d3s7mA_, 0.9365, 0.89, 0.997, 369, 369, PYRAZOLYL AND THIENYL AMINOHYDANTOINS AS POTENT BACE1 INHIBITORS
408, d5i3vA_, 0.9361, 1.16, 0.987, 371, 371, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE COMPOUND 1
409, d5i3xA_, 0.9360, 0.92, 0.992, 370, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE INHIBITOR 6
410, d2zhvA_, 0.9359, 1.14, 0.989, 373, 371, CRYSTAL STRUCTURE OF BACE1 AT PH 7.0
411, d4rcdA_, 0.9357, 0.99, 0.995, 370, 370, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH A 2-AMINOOXAZOLINE 4- AZAXANTHENE INHIBITOR
412, d3in3A_, 0.9356, 0.80, 0.995, 368, 368, BACE1 WITH COMPOUND 30
413, d3fktA_, 0.9356, 1.07, 0.992, 370, 370, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH SPIROPIPERDINE IMINOHYDANTOIN INHIBITOR
414, d3e3wA_, 0.9355, 0.84, 0.992, 368, 368,  
415, d4b05A_, 0.9348, 0.84, 0.992, 368, 368, PRECLINICAL CHARACTERIZATION OF AZD3839 A NOVEL CLINICAL CANDIDATE BACE1 INHIBITOR FOR THE TREATMENT OF ALZHEIMER DISEASE
416, d2zhuA_, 0.9347, 0.98, 0.995, 371, 369, CRYSTAL STRUCTURE OF BACE1 AT PH 5.0
417, d2zhtA_, 0.9347, 1.06, 0.995, 370, 370, CRYSTAL STRUCTURE OF BACE1 AT PH 4.5
418, d2zhsA_, 0.9346, 1.06, 0.992, 370, 370, CRYSTAL STRUCTURE OF BACE1 AT PH 4.0
419, d3rviA_, 0.9345, 1.05, 0.995, 370, 370, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 2-((2-AMINO-6-O- TOLYLQUINOLIN-3-YL)METHYL)-N-(CYCLOHEXYLMETHYL)PENTANAMIDE
420, d3dm6C_, 0.9344, 0.96, 0.995, 369, 369, BETA-SECRETASE 1 COMPLEXED WITH STATINE-BASED INHIBITOR
421, d3buhA_, 0.9343, 0.77, 1.000, 367, 367, BACE-1 COMPLEXED WITH COMPOUND 4
422, d3igbA_, 0.9341, 0.88, 0.995, 370, 368, BACE-1 WITH COMPOUND 3
423, d5i3yA_, 0.9337, 1.05, 0.986, 369, 369, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOQUINOLINE INHIBITOR 9
424, d4dh6A_, 0.9337, 1.02, 0.992, 369, 369, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (2R)-N-((2S3R)- 1-(BENZO[D][13]DIOXOL-5-YL)-3-HYDROXY-4-((S)-6 -NEOPENTYL-3 4 - DIHYDROSPIRO[CYCLOBUTANE-12 -PYRANO[23-B]PYRIDINE]-4 -YLAMINO) BUTAN-2-YL)-2-METHOXYPROPANAMIDE
425, d3rtmA_, 0.9337, 0.77, 0.995, 367, 367, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE
426, d2zdzA_, 0.9336, 0.97, 0.995, 369, 369, X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 3.B.10
427, d3lhgA_, 0.9334, 1.18, 0.989, 370, 370, BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 4G
428, d3in4A_, 0.9333, 1.10, 0.986, 369, 369, BACE1 WITH COMPOUND 38
429, d3indA_, 0.9332, 1.16, 0.992, 370, 370, BACE1 WITH THE AMINOHYDANTOIN COMPOUND 29
430, d4j1kA_, 0.9327, 1.06, 0.989, 370, 369, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R5R6S)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-56-DIHYDRO-4H-[13]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE
431, d3braA_, 0.9327, 0.84, 0.995, 368, 367, BACE-1 COMPLEXED WITH COMPOUND 1
432, d3s7lA_, 0.9326, 0.94, 0.995, 370, 368, PYRAZOLYL AND THIENYL AMINOHYDANTOINS AS POTENT BACE1 INHIBITORS
433, d3oozA_, 0.9323, 1.12, 0.986, 369, 369, BACE1 IN COMPLEX WITH THE AMINOHYDANTOIN COMPOUND 102
434, d3tprA_, 0.9320, 1.02, 0.986, 368, 368, CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR
435, d2ph8A_, 0.9316, 0.93, 0.997, 368, 368, CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE COMPLEXED WITH INHIBITOR
436, d2ewyD_, 0.9312, 0.65, 0.992, 365, 365, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
437, d2ewyC_, 0.9312, 1.36, 0.544, 374, 373, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
438, d2ewyB_, 0.9312, 1.36, 0.544, 374, 373, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
439, d2ewyA_, 0.9312, 1.36, 0.544, 374, 373, CRYSTAL STRUCTURE OF HUMAN BACE2 IN COMPLEX WITH A HYDROXYETHYLENAMINE TRANSITION-STATE INHIBITOR
440, d3ineA_, 0.9298, 1.36, 0.544, 374, 373, BACE1 WITH THE AMINOHYDANTOIN COMPOUND S-34
441, d3zkqA_, 0.9297, 0.99, 0.989, 367, 367, BACE2 XAPERONE COMPLEX
442, d2zjnA_, 0.9293, 1.59, 0.549, 376, 375, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE
443, d3kyrA_, 0.9287, 0.92, 0.995, 367, 367, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
444, d2qu3A_, 0.9281, 0.81, 0.997, 365, 365, BACE1 WITH COMPOUND 2
445, d3rtnA_, 0.9279, 1.21, 0.981, 368, 368, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2-AMINO-6-O- TOLYLQUINOLIN-3-YL)-N-CYCLOHEXYLPROPANAMIDE
446, d4dusA_, 0.9259, 1.01, 0.995, 367, 367, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH N-((2S3R)-1-(4- FLUOROPHENYL)-3-HYDROXY-4-((6 -NEOPENTYL-3 4 - DIHYDROSPIRO[CYCLOBUTANE-12 -PYRANO[23-B]PYRIDIN]-4 -YL)AMINO) BUTAN-2-YL)ACETAMIDE
447, d3inhA_, 0.9251, 0.88, 0.995, 365, 365, BACE1 WITH THE AMINOHYDANTOIN COMPOUND R-58
448, d3infA_, 0.9249, 0.97, 0.992, 366, 365, BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37
449, d4rceA_, 0.9246, 1.12, 0.984, 367, 366, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE INHIBITOR 2
450, d4bfbB_, 0.9240, 0.84, 0.995, 364, 364, BACE2 XAPERONE COMPLEX
451, d4xkxA_, 0.9238, 1.63, 0.552, 374, 373, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 2-AMINOOXAZOLINE 3- AZAXANTHENE INHIBITOR 28
452, d4i1cA1, 0.9228, 0.77, 0.994, 363, 363, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
453, d4bfbA_, 0.9226, 1.09, 1.000, 373, 366, BACE2 XAPERONE COMPLEX
454, d3rsvA_, 0.9215, 1.64, 0.554, 373, 372, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (R)-3-(2-AMINO-6- O-TOLYLQUINOLIN-3-YL)-N-((R)-22-DIMETHYLTETRAHYDRO-2H-PYRAN-4-YL)-2- METHYLPROPANAMIDE
455, d3kyrB_, 0.9212, 0.96, 0.978, 364, 364, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
456, d3l3aA_, 0.9207, 0.89, 0.997, 363, 363, BACE-1 WITH THE AMINOPYRIDINE COMPOUND 32
457, d3l38A_, 0.9204, 1.16, 0.989, 365, 365, BACE1 IN COMPLEX WITH THE AMINOPYRIDINE COMPOUND 44
458, d3kyrC_, 0.9195, 1.10, 0.986, 364, 364, BACE-1 IN COMPLEX WITH A NORSTATINE TYPE INHIBITOR
459, d3ru1A_, 0.9192, 0.63, 0.997, 360, 360, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-(CYCLOHEXYLMETHYL)PROPANAMIDE
460, d3vv7A_, 0.9172, 0.95, 0.975, 363, 363, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-6-((1S2R)- 2-(3 -METHOXYBIPHENYL-3-YL)CYCLOPROPYL)-3-METHYLPYRIMIDIN-4(3H)-ONE
461, d3zkxA_, 0.9171, 0.84, 0.997, 361, 361, TERNARY BACE2 XAPERONE COMPLEX
462, d3wb5A_, 0.9163, 1.47, 0.556, 370, 369, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH (6S)-2-AMINO-36- DIMETHYL-6-[(1R2R)-2-PHENYLCYCLOPROPYL]-3456-TETRAHYDROPYRIMIDIN- 4-ONE
463, d2qu2A_, 0.9156, 0.87, 0.994, 361, 361, BACE1 WITH COMPOUND 1
464, d5ie1A_, 0.9143, 1.35, 0.984, 364, 364, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH 3-(2-AMINO-6-(O-TOLYL) QUINOLIN-3-YL)-N-(33-DIMETHYLBUTYL)PROPANAMIDE
465, d3vv6A_, 0.9140, 0.99, 0.992, 361, 361, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S 2R)-2-PHENYLCYCLOPROPYL)PYRIMIDIN-4(3H)-ONE
466, d3zlqB_, 0.9139, 0.85, 0.997, 360, 360, BACE2 XAPERONE COMPLEX
467, d5enkA_, 0.9127, 1.62, 0.556, 370, 369, COMPOUND 18
468, d5kr8A_, 0.9126, 0.80, 0.997, 359, 359, (4~{S}6~{S})-4-[24-BIS(FLUORANYL)PHENYL]-6-(35-DIMETHYL-12-OXAZOL- 4-YL)-4-METHYL-56-DIHYDRO-13-THIAZIN-2-AMINE (COMPOUND 5) BOUND TO BACE1
469, d2ze1A_, 0.9122, 0.82, 0.997, 359, 359, X-RAY STRUCTURE OF BACE-1 IN COMPLEX WITH COMPOUND 6G
470, d5enmA_, 0.9116, 1.00, 0.994, 360, 360, COMPOUND 10
471, d5kqfA_, 0.9098, 0.85, 0.997, 359, 359, (4~{S}6~{S})-4-[24-BIS(FLUORANYL)PHENYL]-4-METHYL-6-PYRIMIDIN-5-YL- 56-DIHYDRO-13-THIAZIN-2-AMINE (COMPOUND 12) BOUND TO BACE1
472, d3wb4A_, 0.9097, 0.83, 1.000, 358, 358, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-36- DIMETHYL-6-(2-PHENYLETHYL)-3456-TETRAHYDROPYRIMIDIN-4-ONE
473, d4i12A1, 0.9089, 1.00, 0.992, 360, 360, DESIGN AND SYNTHESIS OF THIOPHENE DIHYDROISOQUINOLINS AS NOVEL BACE-1 INHIBITORS
474, d3vv8A_, 0.9086, 1.15, 0.997, 368, 361, CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S2R)-2-(3 -METHYLBIPHENYL-4-YL)CYCLOPROPYL)PYRIMIDIN-4(3H)-ONE
475, d3zkmA_, 0.9068, 0.87, 0.994, 358, 358, BACE2 FAB COMPLEX
476, d3zlqA_, 0.9061, 2.04, 0.543, 375, 370, BACE2 XAPERONE COMPLEX
477, d3zkgA_, 0.9061, 1.64, 0.557, 367, 366, BACE2 MUTANT APO STRUCTURE
478, d2zjhA_, 0.9057, 1.39, 0.567, 364, 363, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE
479, d3zkmB_, 0.9056, 0.77, 0.997, 356, 356, BACE2 FAB COMPLEX
480, d3zknB_, 0.9049, 2.10, 0.541, 375, 370, BACE2 FAB INHIBITOR COMPLEX
481, d3zkiA_, 0.9044, 2.07, 0.543, 375, 370, BACE2 MUTANT STRUCTURE WITH LIGAND
482, d4ke1A_, 0.9043, 1.51, 0.566, 365, 364, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 19
483, d3bufA_, 0.9041, 0.74, 0.994, 355, 355, BACE-1 COMPLEXED WITH COMPOUND 2
484, d3zknA_, 0.9033, 0.97, 0.994, 359, 357, BACE2 FAB INHIBITOR COMPLEX
485, d3bugA_, 0.9027, 2.15, 0.541, 375, 370, BACE-1 COMPLEXED WITH COMPOUND 3
486, d4belA_, 0.8957, 0.92, 0.994, 357, 356, BACE2 XAPERONE COMPLEX
487, d3zkiB_, 0.8945, 1.27, 0.571, 358, 357, BACE2 MUTANT STRUCTURE WITH LIGAND
488, d3zksA_, 0.8943, 1.51, 0.564, 361, 360, BACE2 XAPERONE COMPLEX WITH INHIBITOR
489, d3zkgB_, 0.8936, 1.50, 0.560, 360, 359, BACE2 MUTANT APO STRUCTURE
490, d4belB_, 0.8910, 1.38, 0.567, 359, 358, BACE2 XAPERONE COMPLEX
491, d2zjlA_, 0.8749, 1.31, 0.573, 357, 356, CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-23-DIMETHOXY-BENZYL)-PIPERIDIN- 4-YL]-4-MERCAPTO-BUTYRAMIDE
492, d2rmpA_, 0.7843, 0.78, 0.997, 344, 344, RMP-PEPSTATIN A COMPLEX
493, d2asiA_, 0.7775, 2.55, 0.203, 358, 335, ASPARTIC PROTEINASE
494, d1mppA_, 0.7762, 2.55, 0.203, 358, 335, X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS
495, d1lya.1, 0.7676, 2.57, 0.201, 356, 333, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
496, d1lyb.1, 0.7659, 2.62, 0.219, 357, 334, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
497, d1lya.2, 0.7655, 2.42, 0.284, 338, 324, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
498, d1lyb.2, 0.7641, 2.42, 0.284, 338, 324, CRYSTAL STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN D: IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
499, d1fq8A_, 0.7562, 2.48, 0.284, 338, 324, X-RAY STRUCTURE OF DIFLUOROSTATINE INHIBITOR CP81198 BOUND TO SACCHAROPEPSIN
500, d2jxrA_, 0.7559, 2.50, 0.284, 338, 324, STRUCTURE OF YEAST PROTEINASE A
501, d1jxrA_, 0.7559, 2.53, 0.284, 338, 324,  
502, d1fq6A_, 0.7552, 2.39, 0.252, 329, 318, X-RAY STRUCTURE OF GLYCOL INHIBITOR PD-133450 BOUND TO SACCHAROPEPSIN
503, d1fq7A_, 0.7549, 2.40, 0.252, 329, 318, X-RAY STRUCTURE OF INHIBITOR CP-72647 BOUND TO SACCHAROPEPSIN
504, d1fq4A_, 0.7549, 2.40, 0.252, 329, 318, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN HYDROXYETHYLENE INHIBITOR CP- 108420 AND YEAST ASPARTIC PROTEINASE A
505, d1fq5A_, 0.7544, 2.39, 0.252, 329, 318, X-RAY STRUCTURE OF A CYCLIC STATINE INHIBITOR PD-129541 BOUND TO YEAST PROTEINASE A
506, d2i4qB1, 0.7543, 2.44, 0.248, 329, 318, HUMAN RENIN/PF02342674 COMPLEX
507, d3oqkB_, 0.7538, 2.42, 0.255, 329, 318, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
508, d3oqfB_, 0.7536, 2.42, 0.245, 329, 318, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
509, d3ootB_, 0.7535, 2.67, 0.249, 334, 321, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
510, d2il2B_, 0.7529, 2.62, 0.247, 337, 320, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
511, d3sfcB_, 0.7524, 2.71, 0.249, 337, 321, STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS
512, d2ikuB_, 0.7523, 2.79, 0.248, 337, 322, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS
513, d4gjbB_, 0.7522, 2.75, 0.252, 338, 321, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)
514, d4gj9B_, 0.7521, 2.65, 0.250, 340, 320, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)
515, d4gj8B_, 0.7519, 2.76, 0.249, 337, 321, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)
516, d3vswB_, 0.7511, 2.73, 0.253, 335, 320, HUMAN RENIN IN COMPLEX WITH COMPOUND 8
517, d2g1yB_, 0.7509, 2.71, 0.253, 335, 320, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
518, d2g1sB_, 0.7509, 2.73, 0.253, 335, 320, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
519, d4xx4B_, 0.7508, 2.67, 0.250, 340, 320, RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
520, d2g1nB_, 0.7508, 2.56, 0.252, 333, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
521, d4s1gB_, 0.7507, 2.57, 0.255, 333, 318, REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
522, d2g1rB_, 0.7507, 2.67, 0.251, 338, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
523, d5mlgA1, 0.7505, 2.58, 0.248, 333, 318, CRYSTAL STRUCTURE OF RAT PRORENIN
524, d3q5hB_, 0.7504, 2.67, 0.251, 338, 319, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
525, d3q4bB_, 0.7504, 2.56, 0.252, 333, 318, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
526, d3vsxB_, 0.7503, 2.30, 0.247, 362, 316, HUMAN RENIN IN COMPLEX WITH COMPOUND 18
527, d5v8vA_, 0.7502, 2.30, 0.247, 362, 316, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
528, d1b5f.1, 0.7502, 2.78, 0.249, 338, 321, NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
529, d4aa8A_, 0.7500, 2.83, 0.242, 337, 322, BOVINE CHYMOSIN AT 1.8A RESOLUTION
530, d1bilB_, 0.7500, 2.69, 0.250, 340, 320, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
531, d5v8vB_, 0.7499, 2.84, 0.245, 337, 322, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
532, d4xx3B_, 0.7499, 2.24, 0.242, 326, 314, RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
533, d6aprE_, 0.7498, 2.31, 0.255, 323, 314, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
534, d4aucA_, 0.7498, 2.68, 0.252, 333, 318, BOVINE CHYMOSIN IN COMPLEX WITH PEPSTATIN A
535, d5vpmB_, 0.7497, 2.86, 0.245, 337, 322, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
536, d2g22B_, 0.7497, 2.69, 0.248, 338, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
537, d1qrpE_, 0.7497, 2.45, 0.208, 325, 317, HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL- LEU(P)-(O)PHE-ALA-ALA-OME
538, d3q3tA_, 0.7496, 2.30, 0.258, 323, 314, ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3
539, d4rz1B_, 0.7494, 2.73, 0.244, 335, 320, RENIN IN COMPLEXED WITH (3S4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR
540, d3ownB_, 0.7494, 2.60, 0.255, 333, 318, POTENT MACROCYCLIC RENIN INHIBITORS
541, d2g1oB_, 0.7494, 2.32, 0.273, 326, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
542, d5tmgB_, 0.7492, 2.82, 0.249, 337, 321, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
543, d4gjcB_, 0.7492, 2.66, 0.245, 336, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)
544, d3sfcA_, 0.7492, 2.70, 0.248, 334, 319, STRUCTURE-BASED OPTIMIZATION OF POTENT 4- AND 6-AZAINDOLE-3- CARBOXAMIDES AS RENIN INHIBITORS
545, d3q5hA_, 0.7492, 2.52, 0.246, 333, 317, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
546, d3km4A_, 0.7491, 2.56, 0.252, 334, 317, OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
547, d5aprE_, 0.7490, 2.66, 0.248, 337, 318, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
548, d3aprE_, 0.7490, 2.84, 0.246, 340, 321, BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION
549, d2ikoA_, 0.7490, 2.82, 0.249, 337, 321, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
550, d2g20B_, 0.7490, 2.84, 0.249, 337, 321, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
551, d1bimB_, 0.7490, 2.46, 0.208, 325, 317, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
552, d4rygB_, 0.7489, 2.46, 0.208, 325, 317, RENIN IN COMPLEXED WITH N-({(3S4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR
553, d4gjaB_, 0.7489, 2.82, 0.243, 338, 321, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)
554, d2il2A_, 0.7489, 2.52, 0.249, 333, 317, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
555, d4gjbA_, 0.7488, 2.61, 0.252, 333, 317, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BBV031 (COMPOUND 6)
556, d3vsxA_, 0.7488, 2.67, 0.252, 337, 318, HUMAN RENIN IN COMPLEX WITH COMPOUND 18
557, d1uh7A_, 0.7488, 2.67, 0.248, 337, 318, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6
558, d2ikuA_, 0.7487, 2.83, 0.243, 338, 321, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS
559, d4q1nB_, 0.7486, 2.68, 0.248, 335, 319, STRUCTURE-BASED DESIGN OF 4-HYDROXY-35-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS
560, d2i4qA1, 0.7486, 2.87, 0.242, 340, 322, HUMAN RENIN/PF02342674 COMPLEX
561, d1psoE_, 0.7486, 2.46, 0.208, 325, 317, THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
562, d4gj9A_, 0.7485, 2.46, 0.208, 325, 317, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH GP055321 (COMPOUND 4)
563, d3q4bA_, 0.7485, 2.78, 0.247, 337, 320, CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS
564, d1uh9A_, 0.7485, 2.62, 0.252, 336, 317, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0
565, d1psnA_, 0.7485, 2.72, 0.244, 334, 320, THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN
566, d2aprA_, 0.7484, 2.28, 0.274, 326, 314, STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS
567, d1cziE_, 0.7483, 2.79, 0.247, 333, 320, CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972
568, d4xx4A_, 0.7482, 2.89, 0.245, 337, 322, RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
569, d4rycB_, 0.7482, 2.47, 0.208, 325, 317, RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR
570, d3vydB_, 0.7482, 2.34, 0.270, 326, 315, HUMAN RENIN IN COMPLEX WITH INHIBITOR 6
571, d5kotB_, 0.7481, 2.47, 0.208, 325, 317, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
572, d4xx3A_, 0.7481, 2.30, 0.252, 323, 314, RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
573, d4aprE_, 0.7481, 2.90, 0.242, 339, 322, STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS
574, d2g1yA_, 0.7481, 2.68, 0.248, 336, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
575, d2g1sA_, 0.7481, 2.58, 0.252, 337, 317, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
576, d3vswA_, 0.7480, 2.54, 0.250, 333, 316, HUMAN RENIN IN COMPLEX WITH COMPOUND 8
577, d3gw5A_, 0.7479, 2.91, 0.242, 339, 322, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
578, d4s1gA_, 0.7477, 2.47, 0.208, 325, 317, REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM
579, d1uh8A_, 0.7477, 2.69, 0.245, 333, 319, CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0
580, d4pyvB_, 0.7476, 2.69, 0.245, 333, 319, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4
581, d2g1rA_, 0.7476, 2.86, 0.246, 340, 321, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
582, d4gjdB_, 0.7475, 2.85, 0.249, 337, 321, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)
583, d1m43B_, 0.7473, 2.92, 0.242, 339, 322, CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
584, d2g1nA_, 0.7471, 2.48, 0.208, 325, 317, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
585, d3oqfA_, 0.7470, 2.67, 0.255, 334, 318, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZINE INHIBITOR COMPLEXES
586, d2g1oA_, 0.7470, 2.71, 0.245, 333, 319, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
587, d1hrnB_, 0.7470, 2.61, 0.252, 337, 317, HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
588, d3utlA_, 0.7469, 2.64, 0.226, 331, 319, HUMAN PEPSIN 3B
589, d1flhA_, 0.7469, 2.71, 0.245, 333, 319, CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION
590, d1xdhB_, 0.7468, 2.89, 0.246, 337, 321, STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
591, d1b5f.2, 0.7468, 2.72, 0.245, 333, 319, NATIVE CARDOSIN A FROM CYNARA CARDUNCULUS L.
592, d3vucB_, 0.7467, 2.66, 0.246, 333, 317, HUMAN RENIN IN COMPLEX WITH COMPOUND 5
593, d1dp5A_, 0.7467, 2.32, 0.271, 326, 314, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT INHIBITOR
594, d2g22A_, 0.7466, 2.31, 0.271, 326, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
595, d1f34A_, 0.7466, 2.57, 0.230, 329, 318, CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN
596, d3oqkA_, 0.7464, 2.22, 0.243, 325, 313, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
597, d1g0vA_, 0.7464, 2.67, 0.252, 338, 318, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH A IA3 MUTANT MVV
598, d5pepA_, 0.7463, 2.62, 0.259, 329, 317, X-RAY ANALYSES OF ASPARTIC PROTEASES. II. THREE-DIMENSIONAL STRUCTURE OF THE HEXAGONAL CRYSTAL FORM OF PORCINE PEPSIN AT 2.3 ANGSTROMS RESOLUTION
599, d1fmxA_, 0.7462, 2.62, 0.259, 329, 317, STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
600, d5vpmA_, 0.7461, 2.73, 0.245, 333, 319, CRYSTAL STRUCTURE OF HUMAN RENIN IN COMPLEX WITH A BIPHENYLPIPDERIDINYLCARBINOL
601, d4gj7B_, 0.7461, 2.34, 0.271, 325, 314, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)
602, d4gjaA_, 0.7459, 2.86, 0.243, 337, 321, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5)
603, d3vucA_, 0.7459, 2.59, 0.259, 329, 317, HUMAN RENIN IN COMPLEX WITH COMPOUND 5
604, d3ootA_, 0.7459, 2.35, 0.271, 326, 314, CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES
605, d4rz1A_, 0.7457, 2.38, 0.259, 325, 313, RENIN IN COMPLEXED WITH (3S4S)-4-({[4-METHOXY-3-(3-METHOXYPROPOXY) BENZOYL](PROPAN-2-YL)AMINO}METHYL)PYRROLIDIN-3-YL BENZYLCARBAMATE INHIBITOR
606, d4gjcA_, 0.7456, 2.68, 0.255, 334, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9)
607, d1dpjA_, 0.7455, 2.67, 0.249, 336, 317, THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR
608, d4gj8A_, 0.7454, 2.80, 0.245, 337, 319, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3)
609, d3d91B1, 0.7454, 2.96, 0.245, 340, 322, HUMAN RENIN IN COMPLEX WITH REMIKIREN
610, d4pyvA_, 0.7453, 2.77, 0.250, 337, 320, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH COMPOUND4
611, d3d91A1, 0.7453, 2.82, 0.245, 336, 319, HUMAN RENIN IN COMPLEX WITH REMIKIREN
612, d1yx9A_, 0.7453, 2.81, 0.245, 337, 319, EFFECT OF DIMETHYL SULPHOXIDE ON THE CRYSTAL STRUCTURE OF PORCINE PEPSIN
613, d5kosB_, 0.7452, 2.64, 0.259, 329, 317, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
614, d4gj6B_, 0.7452, 2.75, 0.252, 334, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)
615, d1w6iC_, 0.7452, 2.81, 0.251, 336, 319, PLASMEPSIN II-PEPSTATIN A COMPLEX
616, d1cmsA_, 0.7452, 2.81, 0.245, 335, 319, THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION
617, d2v0zC_, 0.7451, 2.67, 0.246, 333, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
618, d1psaB_, 0.7451, 2.37, 0.271, 326, 314, STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
619, d1psaA_, 0.7451, 2.55, 0.251, 332, 315, STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR
620, d1bilA_, 0.7451, 2.79, 0.251, 333, 319, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
621, d1bimA_, 0.7450, 2.64, 0.230, 329, 318, CRYSTALLOGRAPHIC STUDIES ON THE BINDING MODES OF P2-P3 BUTANEDIAMIDE RENIN INHIBITORS
622, d2g24B_, 0.7449, 2.27, 0.259, 323, 313, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
623, d2g21B_, 0.7449, 2.27, 0.259, 323, 313, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
624, d1hrnA_, 0.7449, 2.87, 0.244, 338, 320, HIGH RESOLUTION CRYSTAL STRUCTURES OF RECOMBINANT HUMAN RENIN IN COMPLEX WITH POLYHYDROXYMONOAMIDE INHIBITORS
625, d4rygA_, 0.7448, 2.38, 0.271, 326, 314, RENIN IN COMPLEXED WITH N-({(3S4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR
626, d3ownA_, 0.7448, 2.44, 0.267, 326, 315, POTENT MACROCYCLIC RENIN INHIBITORS
627, d1smrG_, 0.7448, 2.72, 0.248, 334, 318, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
628, d1smrE_, 0.7448, 2.80, 0.248, 334, 319, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
629, d1smrC_, 0.7448, 2.46, 0.252, 329, 314, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
630, d1smrA_, 0.7448, 2.46, 0.252, 329, 314, THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN
631, d1fmxB_, 0.7447, 2.84, 0.248, 334, 319, STRUCTURE OF NATIVE PROTEINASE A IN THE SPACE GROUP P21
632, d3vyfB_, 0.7446, 2.82, 0.245, 336, 319, HUMAN RENIN IN COMPLEX WITH INHIBITOR 9
633, d1xe6B_, 0.7445, 2.84, 0.245, 334, 319, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
634, d4gj5B_, 0.7444, 2.59, 0.249, 331, 317, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)
635, d3vydA_, 0.7444, 2.59, 0.249, 331, 317, HUMAN RENIN IN COMPLEX WITH INHIBITOR 6
636, d3vyeB_, 0.7442, 2.59, 0.249, 331, 317, HUMAN RENIN IN COMPLEX WITH INHIBITOR 7
637, d2v16O_, 0.7442, 2.59, 0.249, 331, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
638, d4cmsA_, 0.7441, 2.36, 0.259, 325, 313, X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN
639, d1xe5B_, 0.7441, 2.56, 0.254, 335, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
640, d1am5A_, 0.7441, 2.52, 0.233, 329, 317, THE CRYSTAL STRUCTURE AND PROPOSED AMINO ACID SEQUENCE OF A PEPSIN FROM ATLANTIC COD (GADUS MORHUA)
641, d4q1nA_, 0.7440, 2.65, 0.250, 331, 316, STRUCTURE-BASED DESIGN OF 4-HYDROXY-35-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS
642, d4gj6A_, 0.7440, 2.74, 0.245, 337, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A)
643, d3pepA_, 0.7440, 2.58, 0.254, 335, 315, REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN
644, d3cmsA_, 0.7439, 2.70, 0.249, 331, 317, ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN
645, d5koqA_, 0.7437, 2.37, 0.256, 320, 313, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
646, d3q3tB_, 0.7437, 2.53, 0.230, 329, 317, ALKYL AMINE RENIN INHIBITORS: FILLING S1 FROM S3
647, d3g72B_, 0.7437, 2.29, 0.275, 324, 313, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
648, d1me6B_, 0.7437, 2.79, 0.245, 336, 318, CRYSTAL STRUCTURE OF PLASMEPSIN II AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH A STATINE-BASED INHIBITOR
649, d5tmkB_, 0.7436, 2.79, 0.248, 333, 319, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
650, d5koqB_, 0.7436, 2.38, 0.268, 326, 314, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
651, d2g20A_, 0.7436, 2.26, 0.260, 320, 312, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
652, d1wkrA_, 0.7436, 2.84, 0.244, 335, 320, CRYSTAL STRUCTURE OF ASPARTIC PROTEINASE FROM IRPEX LACTEUS
653, d1bbsB_, 0.7436, 2.75, 0.248, 333, 318, X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
654, d1bbsA_, 0.7436, 2.69, 0.256, 336, 317, X-RAY ANALYSES OF PEPTIDE INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS
655, d1smeB_, 0.7435, 2.67, 0.230, 329, 318, PLASMEPSIN II A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH PEPSTATIN A
656, d2v10O_, 0.7433, 2.48, 0.249, 330, 313, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
657, d2v0zO_, 0.7433, 2.63, 0.244, 333, 316, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN)
658, d4rycA_, 0.7430, 2.77, 0.245, 333, 319, RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR
659, d4gjdA_, 0.7430, 2.80, 0.242, 340, 318, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12)
660, d5tmgA_, 0.7428, 2.80, 0.242, 340, 318, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
661, d4gj5A_, 0.7428, 2.68, 0.249, 331, 317, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5)
662, d3k1wB1, 0.7428, 2.68, 0.249, 331, 317, NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS
663, d3g72A_, 0.7428, 2.70, 0.230, 329, 318, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
664, d2v11O_, 0.7426, 2.57, 0.254, 331, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
665, d3g70B1, 0.7423, 2.67, 0.247, 336, 316, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
666, d4pepA_, 0.7422, 2.86, 0.245, 336, 319, THE MOLECULAR AND CRYSTAL STRUCTURES OF MONOCLINIC PORCINE PEPSIN REFINED AT 1.8 ANGSTROMS RESOLUTION
667, d3km4B_, 0.7422, 2.82, 0.245, 335, 318, OPTIMIZATION OF ORALLY BIOAVAILABLE ALKYL AMINE RENIN INHIBITORS
668, d3vyeA_, 0.7421, 2.86, 0.245, 334, 319, HUMAN RENIN IN COMPLEX WITH INHIBITOR 7
669, d4gj7A_, 0.7417, 2.67, 0.250, 332, 316, CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCA079 (COMPOUND 12A)
670, d3vyfA_, 0.7417, 2.80, 0.255, 336, 318, HUMAN RENIN IN COMPLEX WITH INHIBITOR 9
671, d2g21A_, 0.7416, 2.79, 0.248, 333, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
672, d3gw5B_, 0.7414, 2.67, 0.250, 331, 316, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR
673, d2g24A_, 0.7414, 2.77, 0.252, 336, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
674, d3g70A1, 0.7411, 2.38, 0.272, 325, 313, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
675, d1ls5B_, 0.7411, 2.79, 0.252, 333, 317, CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
676, d1fmuA_, 0.7410, 2.80, 0.246, 335, 317, STRUCTURE OF NATIVE PROTEINASE A IN P3221 SPACE GROUP.
677, d2fs4A_, 0.7409, 2.83, 0.245, 335, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
678, d2bksA_, 0.7409, 2.85, 0.245, 336, 318, CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX
679, d5sy2A_, 0.7408, 2.61, 0.248, 329, 315, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
680, d1jgfB_, 0.7408, 2.76, 0.249, 332, 317,  
681, d2g26A_, 0.7404, 2.63, 0.244, 329, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
682, d3k1wA1, 0.7400, 2.82, 0.248, 333, 318, NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS
683, d3g6zA1, 0.7400, 2.66, 0.223, 328, 318, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
684, d5tmkA_, 0.7399, 2.25, 0.251, 322, 311, OPTIMIZATION OF 35-DISUBSTITUED PIPERIDINE: DISCOVERY OF NON-PEPTIDE MIMETICS AS AN ORALLY ACTIVE RENIN INHIBITOR
685, d2qzxB_, 0.7397, 2.64, 0.248, 329, 315, SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
686, d3g6zB1, 0.7394, 2.64, 0.248, 329, 315, DESIGN AND PREPARATION OF POTENT NON-PEPTIDIC BIOAVAILABLE RENIN INHIBITORS
687, d2v11C_, 0.7393, 2.76, 0.246, 335, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6
688, d1xdhA_, 0.7393, 2.65, 0.226, 328, 318, STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A
689, d4ckuB_, 0.7392, 2.65, 0.244, 329, 315, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
690, d1rneA_, 0.7391, 2.80, 0.249, 332, 317, THE CRYSTAL STRUCTURE OF RECOMBINANT GLYCOSYLATED HUMAN RENIN ALONE AND IN COMPLEX WITH A TRANSITION STATE ANALOG INHIBITOR
691, d2bktB_, 0.7390, 2.76, 0.252, 336, 317, CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX
692, d1jgfA_, 0.7390, 2.87, 0.245, 333, 318,  
693, d2v10C_, 0.7389, 2.63, 0.235, 342, 315, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 9
694, d2v16C_, 0.7388, 2.76, 0.249, 333, 317, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 3
695, d1w6iA_, 0.7387, 2.80, 0.246, 333, 317, PLASMEPSIN II-PEPSTATIN A COMPLEX
696, d1me6A_, 0.7383, 2.71, 0.233, 329, 318, CRYSTAL STRUCTURE OF PLASMEPSIN II AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH A STATINE-BASED INHIBITOR
697, d1m43A_, 0.7383, 2.60, 0.228, 327, 316, CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A
698, d1w6hA_, 0.7381, 2.76, 0.244, 329, 315, NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
699, d5kotA_, 0.7379, 2.67, 0.248, 329, 315, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
700, d2qzxA_, 0.7377, 2.63, 0.227, 328, 317, SECRETED ASPARTIC PROTEINASE (SAP) 5 FROM CANDIDA ALBICANS
701, d1lf3A_, 0.7377, 2.80, 0.246, 333, 317, CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR EH58
702, d4ckuF_, 0.7376, 2.80, 0.246, 333, 317, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
703, d2ikoB_, 0.7376, 2.73, 0.233, 329, 318, CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR
704, d2g27B_, 0.7376, 2.74, 0.230, 329, 318, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
705, d2r9bA_, 0.7375, 2.83, 0.226, 331, 319, STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
706, d2g26B_, 0.7375, 2.48, 0.229, 325, 314, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
707, d1xe6A_, 0.7373, 2.78, 0.244, 332, 316, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
708, d1xe5A_, 0.7373, 2.66, 0.238, 342, 315, STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE
709, d1smeA_, 0.7370, 2.66, 0.238, 342, 315, PLASMEPSIN II A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM IN COMPLEX WITH PEPSTATIN A
710, d2bktA_, 0.7368, 2.82, 0.223, 331, 319, CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX
711, d1ls5A_, 0.7368, 2.78, 0.220, 329, 318, CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A
712, d2fs4B_, 0.7366, 2.76, 0.248, 332, 315, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
713, d2bksB_, 0.7366, 2.55, 0.249, 328, 313, CRYSTAL STRUCTURE OF RENIN-PF00074777 COMPLEX
714, d1w6hB_, 0.7363, 2.73, 0.233, 329, 318, NOVEL PLASMEPSIN II-INHIBITOR COMPLEX
715, d1qs8B_, 0.7363, 2.60, 0.252, 329, 314, CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
716, d2v13A_, 0.7359, 2.75, 0.230, 329, 318, CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 7
717, d2r9bB_, 0.7350, 2.76, 0.230, 329, 318, STRUCTURAL ANALYSIS OF PLASMEPSIN 2 FROM PLASMODIUM FALCIPARUM COMPLEXED WITH A PEPTIDE-BASED INHIBITOR
718, d5kosA_, 0.7349, 2.79, 0.230, 329, 318, DISCOVERY OF TAK-272: A NOVEL POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR
719, d2g27A_, 0.7346, 2.70, 0.253, 329, 316, KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING
720, d1avf.2, 0.7346, 2.74, 0.223, 328, 318, ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
721, d2renA_, 0.7344, 2.62, 0.252, 329, 314, STRUCTURE OF RECOMBINANT HUMAN RENIN A TARGET FOR CARDIOVASCULAR- ACTIVE DRUGS AT 2.5 ANGSTROMS RESOLUTION
722, d2bjuA1, 0.7341, 2.62, 0.252, 329, 314, PLASMEPSIN II COMPLEXED WITH A HIGHLY ACTIVE ACHIRAL INHIBITOR
723, d2psgA_, 0.7337, 2.55, 0.229, 325, 314, REFINED STRUCTURE OF PORCINE PEPSINOGEN AT 1.8 ANGSTROMS RESOLUTION
724, d1lf2A_, 0.7334, 2.74, 0.224, 328, 317, CRYSTAL STRUCTURE OF PLASMEPSIN II FROM P FALCIPARUM IN COMPLEX WITH INHIBITOR RS370
725, d1leeA_, 0.7333, 2.70, 0.252, 329, 314, CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367
726, d3f9qA_, 0.7331, 2.73, 0.233, 329, 317, RE-REFINEMENT OF UNCOMPLEXED PLASMEPSIN II FROM PLASMODIUM FALCIPARUM.
727, d4ckuD_, 0.7330, 2.79, 0.248, 331, 315, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
728, d3emyA_, 0.7330, 2.71, 0.248, 328, 315, CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN A
729, d1lyw.4, 0.7330, 2.46, 0.250, 344, 312, CATHEPSIN D AT PH 7.5
730, d1lyw.2, 0.7321, 2.24, 0.254, 320, 307, CATHEPSIN D AT PH 7.5
731, d1lyw.1, 0.7318, 2.80, 0.230, 329, 318, CATHEPSIN D AT PH 7.5
732, d1lyw.3, 0.7313, 2.56, 0.272, 369, 313, CATHEPSIN D AT PH 7.5
733, d4y6mA_, 0.7307, 2.84, 0.233, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
734, d1epmE_, 0.7302, 2.91, 0.232, 331, 319, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
735, d1lf4A_, 0.7301, 2.58, 0.232, 325, 314, STRUCTURE OF PLASMEPSIN II
736, d1qdmA2, 0.7300, 2.46, 0.231, 323, 312, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
737, d4er2E_, 0.7299, 2.74, 0.228, 328, 316, THE ACTIVE SITE OF ASPARTIC PROTEINASES
738, d1epqE_, 0.7298, 2.83, 0.294, 336, 316, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-133 450 (SOT PHE GLY+SCC GCL)
739, d4er1E_, 0.7297, 2.80, 0.295, 336, 315, THE ACTIVE SITE OF ASPARTIC PROTEINASES
740, d1eppE_, 0.7297, 2.87, 0.294, 336, 316, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-130 693 (MAS PHE LYS+MTF STA MBA)
741, d1epnE_, 0.7296, 2.87, 0.294, 336, 316, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
742, d4y6mB_, 0.7295, 2.96, 0.220, 329, 318, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
743, d4ckuA_, 0.7294, 2.72, 0.241, 330, 315, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
744, d3er5E_, 0.7294, 2.60, 0.230, 325, 313, THE ACTIVE SITE OF ASPARTIC PROTEINASES
745, d3c9xA_, 0.7294, 2.40, 0.279, 332, 308, CRYSTAL STRUCTURE OF TRICHODERMA REESEI ASPARTIC PROTEINASE
746, d2igyA_, 0.7294, 2.73, 0.241, 330, 315, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
747, d2er7E_, 0.7294, 2.73, 0.241, 330, 315, X-RAY ANALYSES OF ASPARTIC PROTEINASES.III. THREE-DIMENSIONAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH A TRANSITION-STATE ISOSTERE INHIBITOR OF RENIN AT 1.6 ANGSTROMS RESOLUTION
748, d1entE_, 0.7294, 2.73, 0.241, 330, 315, X-RAY ANALYSES OF ASPARTIC PROTEINASES. THE THREE-DIMENSIONAL STRUCTURE AT 2.1 ANGSTROMS RESOLUTION OF ENDOTHIAPEPSIN
749, d2igyB_, 0.7293, 2.73, 0.241, 330, 315, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
750, d1avf.1, 0.7293, 2.73, 0.241, 330, 315, ACTIVATION INTERMEDIATE 2 OF HUMAN GASTRICSIN FROM HUMAN STOMACH
751, d1eedP_, 0.7292, 2.93, 0.224, 328, 317, X-RAY CRYSTALLOGRAPHIC ANALYSIS OF INHIBITION OF ENDOTHIAPEPSIN BY CYCLOHEXYL RENIN INHIBITORS
752, d5sy2B_, 0.7291, 2.61, 0.221, 323, 312, STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS
753, d5er2E_, 0.7291, 2.74, 0.241, 330, 315, HIGH-RESOLUTION X-RAY DIFFRACTION STUDY OF THE COMPLEX BETWEEN ENDOTHIAPEPSIN AND AN OLIGOPEPTIDE INHIBITOR. THE ANALYSIS OF THE INHIBITOR BINDING AND DESCRIPTION OF THE RIGID BODY SHIFT IN THE ENZYME
754, d1er8E_, 0.7291, 2.80, 0.228, 328, 316, THE ACTIVE SITE OF ASPARTIC PROTEINASES
755, d3er3E_, 0.7289, 2.99, 0.223, 329, 318, THE ACTIVE SITE OF ASPARTIC PROTEINASES
756, d4amtA_, 0.7288, 2.73, 0.241, 330, 315, CRYSTAL STRUCTURE AT 2.6A OF HUMAN PRORENIN
757, d2er0E_, 0.7286, 2.73, 0.241, 330, 315, X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES
758, d1qs8A_, 0.7286, 2.96, 0.230, 329, 318, CRYSTAL STRUCTURE OF THE P. VIVAX ASPARTIC PROTEINASE PLASMEPSIN COMPLEXED WITH THE INHIBITOR PEPSTATIN A
759, d4ckuC_, 0.7285, 2.47, 0.242, 341, 310, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
760, d1eprE_, 0.7281, 2.73, 0.241, 330, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH PD-135 040
761, d1htr.1, 0.7280, 2.64, 0.248, 330, 310, CRYSTAL AND MOLECULAR STRUCTURES OF HUMAN PROGASTRICSIN AT 1.62 ANGSTROMS RESOLUTION
762, d4z22B_, 0.7276, 2.74, 0.241, 330, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A
763, d4ckuE_, 0.7275, 2.74, 0.241, 330, 315, THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR
764, d3psgA_, 0.7273, 2.74, 0.241, 330, 315, THE HIGH RESOLUTION CRYSTAL STRUCTURE OF PORCINE PEPSINOGEN
765, d3urjA_, 0.7272, 2.51, 0.252, 349, 310, TYPE IV NATIVE ENDOTHIAPEPSIN
766, d4y6mC_, 0.7271, 2.75, 0.241, 330, 315, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418
767, d2igxA_, 0.7271, 2.79, 0.225, 327, 315, ACHIRAL CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II
768, d3urlA_, 0.7270, 2.58, 0.225, 322, 311, ENDOTHIAPEPSIN-DB6 COMPLEX.
769, d3fv3C_, 0.7267, 2.77, 0.241, 329, 315, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
770, d1qdmB2, 0.7266, 3.00, 0.252, 372, 317, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
771, d1gktA_, 0.7266, 3.00, 0.252, 372, 317, NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH TRANSITION STATE ANALOGUE INHIBITOR H261
772, d1bxoA_, 0.7266, 2.99, 0.223, 329, 318, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL CYCLO[(2S)-2-[[(1R)-1-(N-(L-N-(3- METHYLBUTANOYL)VALYL-L-ASPARTYL)AMINO)-3-METHYLBUT YL] HYDROXYPHOSPHINYLOXY]-3-(3-AMINOMETHYL) PHENYLPROPANOATE
773, d3fv3A_, 0.7265, 2.60, 0.225, 322, 311, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
774, d2vs2A_, 0.7265, 2.39, 0.276, 365, 308, NEUTRON DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
775, d2jjiA_, 0.7265, 2.78, 0.241, 328, 315, ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
776, d1bxqA_, 0.7264, 3.08, 0.220, 329, 318, ACID PROTEINASE (PENICILLOPEPSIN) COMPLEX WITH PHOSPHONATE INHIBITOR.
777, d3uriA_, 0.7263, 2.97, 0.230, 329, 318, ENDOTHIAPEPSIN-DB5 COMPLEX.
778, d1ppmE_, 0.7263, 2.79, 0.241, 328, 315, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
779, d1aptE_, 0.7263, 2.65, 0.213, 339, 310, CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
780, d2webA_, 0.7262, 2.50, 0.269, 332, 308, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L- VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3- PHENYLPROPANOATE SODIUM SALT
781, d1gvxA_, 0.7262, 2.79, 0.241, 328, 315, ENDOTHIAPEPSIN COMPLEXED WITH H256
782, d1oexA_, 0.7261, 2.63, 0.228, 323, 311, ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261
783, d1apvE_, 0.7261, 2.65, 0.213, 339, 310, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
784, d1ppkE_, 0.7260, 2.65, 0.213, 339, 310, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHOROUS-CONTAINING PEPTIDE ANALOGUES
785, d1epoE_, 0.7260, 2.79, 0.241, 328, 315, ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81282 (MOR PHE NLE CHF NME)
786, d1apwE_, 0.7260, 2.79, 0.241, 328, 315, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES
787, d1apuE_, 0.7260, 2.63, 0.228, 323, 311, CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
788, d3fv3H_, 0.7259, 2.80, 0.241, 328, 315, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
789, d3fv3G_, 0.7259, 2.65, 0.228, 323, 311, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
790, d2qzwA_, 0.7259, 2.64, 0.228, 323, 311, SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
791, d2h6tA_, 0.7259, 2.64, 0.228, 323, 311, SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS COMPLEXED WITH PEPSTATIN A
792, d1oewA_, 0.7259, 2.81, 0.241, 328, 315, ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN
793, d1gvtA_, 0.7259, 2.80, 0.241, 328, 315, ENDOTHIAPEPSIN COMPLEX WITH CP-80794
794, d1j71A_, 0.7258, 2.65, 0.228, 323, 311, STRUCTURE OF THE EXTRACELLULAR ASPARTIC PROTEINASE FROM CANDIDA TROPICALIS YEAST.
795, d1gvvA_, 0.7258, 2.65, 0.228, 323, 311, FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM
796, d1eplE_, 0.7258, 2.78, 0.242, 330, 314, A STRUCTURAL COMPARISON OF 21 INHIBITOR COMPLEXES OF THE ASPARTIC PROTEINASE FROM ENDOTHIA PARASITICA
797, d1e5oE_, 0.7258, 2.65, 0.228, 323, 311, ENDOTHIAPEPSIN COMPLEX WITH INHIBITOR DB2
798, d4z22A_, 0.7257, 2.64, 0.228, 323, 311, STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR DR718A
799, d2wecA_, 0.7257, 2.67, 0.213, 339, 310, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-(1- NAPHTHALENEACETYL))-L-VALYL)AMINOMETHYL)HYDROXY PHOSPHINYLOXY]-3-PHENYLPROPANOATE SODIUM SALT
800, d1gvwA_, 0.7256, 2.68, 0.213, 339, 310, ENDOTHIAPEPSIN COMPLEX WITH PD-130328
801, d2wedA_, 0.7255, 2.91, 0.213, 341, 314, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)- ((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2- PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE] SODIUM SALT
802, d2jjjA_, 0.7254, 2.88, 0.217, 340, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR.
803, d2er6E_, 0.7254, 2.80, 0.241, 328, 315, THE STRUCTURE OF A SYNTHETIC PEPSIN INHIBITOR COMPLEXED WITH ENDOTHIAPEPSIN.
804, d4er4E_, 0.7253, 2.79, 0.241, 328, 315, HIGH-RESOLUTION X-RAY ANALYSES OF RENIN INHIBITOR-ASPARTIC PROTEINASE COMPLEXES
805, d3fv3E_, 0.7252, 2.74, 0.199, 334, 311, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
806, d3wz8A_, 0.7251, 2.80, 0.241, 328, 315, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (8)
807, d1zapA_, 0.7251, 2.80, 0.242, 330, 314, SECRETED ASPARTIC PROTEASE FROM C. ALBICANS
808, d2er9E_, 0.7250, 2.80, 0.239, 330, 314, X-RAY STUDIES OF ASPARTIC PROTEINASE-STATINE INHIBITOR COMPLEXES.
809, d1pplE_, 0.7250, 2.80, 0.239, 330, 314, CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES
810, d1gvuA_, 0.7250, 3.01, 0.223, 329, 318, ENDOTHIAPEPSIN COMPLEX WITH H189
811, d5p3kA_, 0.7249, 2.62, 0.232, 323, 310, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 173
812, d5er1E_, 0.7249, 2.82, 0.241, 328, 315, A RATIONAL APPROACH TO THE DESIGN OF ANTIHYPERTENSIVES. X-RAY STUDIES OF COMPLEXES BETWEEN ASPARTIC PROTEINASES AND AMINOALCOHOL RENIN INHIBITORS
813, d4apeA_, 0.7249, 2.66, 0.228, 323, 311, THE ACTIVE SITE OF ASPARTIC PROTEINASES
814, d3fv3B_, 0.7249, 2.80, 0.241, 328, 315, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
815, d5hcoA_, 0.7248, 2.83, 0.241, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH HYDRAZIDE
816, d4lbtA_, 0.7248, 2.82, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH 100MM ACYLHYDRAZONE INHIBITOR
817, d5p3pA_, 0.7247, 2.59, 0.214, 339, 309, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 178
818, d3fv3F_, 0.7247, 2.79, 0.239, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
819, d1e81E_, 0.7247, 2.96, 0.229, 341, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD61395
820, d5p1qA_, 0.7246, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 109
821, d5oz1A_, 0.7246, 2.68, 0.228, 323, 311, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 12
822, d5oyrA_, 0.7246, 2.82, 0.241, 328, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 2
823, d5hctA_, 0.7246, 2.80, 0.242, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH BIACYLHYDRAZONE
824, d4y3qA_, 0.7246, 2.84, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 109
825, d4kupA_, 0.7246, 2.84, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH 20MM ACYLHYDRAZONE INHIBITOR
826, d5p6wA_, 0.7245, 2.69, 0.213, 339, 310, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 293
827, d5p3rA_, 0.7245, 2.83, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 180
828, d5p1kA_, 0.7245, 2.83, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 103
829, d4y48A_, 0.7245, 2.80, 0.242, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B50
830, d4y3mA_, 0.7245, 2.71, 0.213, 339, 310, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 103
831, d5p0cA_, 0.7244, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 59
832, d3wz7A_, 0.7244, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (6)
833, d1e82E_, 0.7244, 2.81, 0.242, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD59601
834, d5oyzA_, 0.7243, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 10
835, d5oyxA_, 0.7243, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 8
836, d3pbzA_, 0.7243, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
837, d1ibqA_, 0.7243, 2.80, 0.239, 330, 314, ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
838, d5p5bA_, 0.7242, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 236
839, d5p3nA_, 0.7242, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 176
840, d5p0eA_, 0.7242, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 61
841, d5oysA_, 0.7242, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 3
842, d4y3jA_, 0.7242, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B30
843, d3pmuA_, 0.7242, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
844, d5p7cA_, 0.7241, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 309
845, d5p62A_, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 263
846, d5p5dA_, 0.7241, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 238
847, d5p4aA_, 0.7241, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 199
848, d5p41A_, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 190
849, d5p3yA_, 0.7241, 2.76, 0.230, 325, 313, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 187
850, d5p3bA_, 0.7241, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 164
851, d5oz4A_, 0.7241, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 15
852, d5oz2A_, 0.7241, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 13
853, d5oyyA_, 0.7241, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 9
854, d4yd5A_, 0.7241, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 236
855, d4y44A_, 0.7241, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 164
856, d4lhhA_, 0.7241, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH 2MM ACYLHYDRAZONE INHIBITOR
857, d5p82A_, 0.7240, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 335
858, d5p6kA_, 0.7240, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 281
859, d5p2nA_, 0.7240, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 141
860, d5p00A_, 0.7240, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 47
861, d5ozlA_, 0.7240, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 32
862, d4y36A_, 0.7240, 2.81, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 4
863, d4lp9A_, 0.7240, 2.81, 0.242, 330, 314, ENDOTHIAPEPSIN COMPLEXED WITH PHE-REDUCED-TYR PEPTIDE.
864, d3tneB_, 0.7240, 2.81, 0.239, 330, 314, THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR
865, d5p8uA_, 0.7239, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 363
866, d5p6nA_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 284
867, d5p66A_, 0.7239, 2.81, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 267
868, d5p63A_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 264
869, d5p60A_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 261
870, d5p51A_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 226
871, d5p4tA_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 218
872, d5p4dA_, 0.7239, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 202
873, d5p40A_, 0.7239, 2.85, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 189
874, d5p3sA_, 0.7239, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 181
875, d5p3aA_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 163
876, d5p2eA_, 0.7239, 2.60, 0.217, 339, 309, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 132
877, d5p2bA_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 129
878, d5p26A_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 124
879, d5oywA_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 7
880, d5oytA_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 4
881, d5oyqA_, 0.7239, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 1
882, d4y5cA_, 0.7239, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 267
883, d4y5bA_, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 261
884, d4y4jA_, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B97
885, d4y3hA_, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 189
886, d4y3aA_, 0.7239, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 181
887, d5p8hA_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 350
888, d5p7qA_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 323
889, d5p7jA_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 316
890, d5p75A_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 302
891, d5p6vA_, 0.7238, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 292
892, d5p6iA_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 279
893, d5p5qA_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 251
894, d5p58A_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 233
895, d5p4wA_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 221
896, d5p4pA_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 214
897, d5p4lA_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 210
898, d5p47A_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 196
899, d5p46A_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 195
900, d5p43A_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 192
901, d5p3lA_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 174
902, d5p37A_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 160
903, d5p33A_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 156
904, d5p2xA_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 150
905, d5p2jA_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 137
906, d5p2fA_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 133
907, d5p29A_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 127
908, d5p03A_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 50
909, d5p02A_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 49
910, d5ozyA_, 0.7238, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 45
911, d5oz9A_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 20
912, d5oz3A_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 14
913, d5oyvA_, 0.7238, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 6
914, d4y4bA_, 0.7238, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 323
915, d3tneA_, 0.7238, 2.83, 0.239, 330, 314, THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR
916, d5p7uA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 327
917, d5p7rA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 324
918, d5p76A_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 303
919, d5p6xA_, 0.7237, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 294
920, d5p6cA_, 0.7237, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 273
921, d5p64A_, 0.7237, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 265
922, d5p5kA_, 0.7237, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 245
923, d5p5eA_, 0.7237, 2.81, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 239
924, d5p50A_, 0.7237, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 225
925, d5p4zA_, 0.7237, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 224
926, d5p4uA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 219
927, d5p4nA_, 0.7237, 2.60, 0.217, 339, 309, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 212
928, d5p42A_, 0.7237, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 191
929, d5p3wA_, 0.7237, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 185
930, d5p3uA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 183
931, d5p3tA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 182
932, d5p3eA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 167
933, d5p34A_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 157
934, d5p2zA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 152
935, d5p2yA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 151
936, d5p2qA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 143
937, d5p2iA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 136
938, d5p20A_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 119
939, d5p1zA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 118
940, d5p1vA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 114
941, d5p1cA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 95
942, d5ozvA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 42
943, d5ozuA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 41
944, d5ozqA_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 37
945, d5oz8A_, 0.7237, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 19
946, d4yd3A_, 0.7237, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 224
947, d4y4uA_, 0.7237, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 14
948, d4y4tA_, 0.7237, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 114
949, d4y43A_, 0.7237, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 42
950, d4y3zA_, 0.7237, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 41
951, d4y3nA_, 0.7237, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 273
952, d4y38A_, 0.7237, 2.82, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B29
953, d2weaA_, 0.7237, 2.86, 0.238, 330, 315, ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL[CYCLO-7[(2R)-((N-VALYL) AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2-PHENYLETHOXY) PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE] SODIUM SALT
954, d1qdmC2, 0.7237, 2.82, 0.242, 330, 314, CRYSTAL STRUCTURE OF PROPHYTEPSIN A ZYMOGEN OF A BARLEY VACUOLAR ASPARTIC PROTEINASE.
955, d5p6jA_, 0.7236, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 280
956, d5p68A_, 0.7236, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 269
957, d5p65A_, 0.7236, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 266
958, d5p61A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 262
959, d5p5yA_, 0.7236, 2.83, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 259
960, d5p5xA_, 0.7236, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 258
961, d5p5wA_, 0.7236, 2.82, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 257
962, d5p5rA_, 0.7236, 2.82, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 252
963, d5p5lA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 246
964, d5p55A_, 0.7236, 2.85, 0.241, 329, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 230
965, d5p4fA_, 0.7236, 2.69, 0.228, 323, 311, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 204
966, d5p4bA_, 0.7236, 2.54, 0.264, 329, 307, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 200
967, d5p49A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 198
968, d5p45A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 194
969, d5p3mA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 175
970, d5p3gA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 169
971, d5p3dA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 166
972, d5p32A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 155
973, d5p31A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 154
974, d5p2gA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 134
975, d5p2dA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 131
976, d5p2aA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 128
977, d5p28A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 126
978, d5p25A_, 0.7236, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 123
979, d5p1fA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 98
980, d5p0hA_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 64
981, d5p01A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 48
982, d5oz7A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 18
983, d5oz5A_, 0.7236, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 16
984, d5dq2A_, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 48
985, d4y4eA_, 0.7236, 2.86, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 131
986, d4y4dA_, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B51
987, d4y3dA_, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 321
988, d3prsA_, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH RITONAVIR
989, d3pm4A_, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
990, d1e80E_, 0.7236, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD56133
991, d5p8oA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 357
992, d5p8fA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 348
993, d5p80A_, 0.7235, 2.83, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 333
994, d5p7sA_, 0.7235, 2.83, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 325
995, d5p77A_, 0.7235, 2.85, 0.241, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 304
996, d5p72A_, 0.7235, 2.83, 0.242, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 299
997, d5p71A_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 298
998, d5p6sA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 289
999, d5p6qA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 287
1000, d5p6pA_, 0.7235, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 286
1001, d5p6gA_, 0.7235, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 277
1002, d5p6fA_, 0.7235, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 276
1003, d5p6eA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 275
1004, d5p67A_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 268
1005, d5p5oA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 249
1006, d5p5mA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 247
1007, d5p5jA_, 0.7235, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 244
1008, d5p5gA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 241
1009, d5p5cA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 237
1010, d5p5aA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 235
1011, d5p59A_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 234
1012, d5p4vA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 220
1013, d5p4eA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 203
1014, d5p4cA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 201
1015, d5p48A_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 197
1016, d5p3jA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 172
1017, d5p39A_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 162
1018, d5p36A_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 159
1019, d5p30A_, 0.7235, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 153
1020, d5p2vA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 148
1021, d5p2oA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 142
1022, d5p2hA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 135
1023, d5p23A_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 121
1024, d5p1sA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 111
1025, d5p1rA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 110
1026, d5p1oA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 107
1027, d5p1eA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 97
1028, d5p19A_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 92
1029, d5p0sA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 75
1030, d5p0qA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 73
1031, d5p0nA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 70
1032, d5oznA_, 0.7235, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 34
1033, d5mb3A_, 0.7235, 2.83, 0.239, 330, 314, FRAGMENT 333 AT A CONCENTRATION OF 50MM IN COMPLEX WITH ENDOTHIAPEPSIN
1034, d5is4A_, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL BROMINATED PRIMARY AMINE FRAGMENT
1035, d5dr3A_, 0.7235, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 333
1036, d4y5kA_, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 274
1037, d4y5eA_, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 268
1038, d4y4zA_, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 73
1039, d4y4gA_, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B53
1040, d4y3sA_, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 266
1041, d4y39A_, 0.7235, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 75
1042, d3appA_, 0.7235, 2.83, 0.239, 330, 314, STRUCTURE AND REFINEMENT OF PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION
1043, d5p8eA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 347
1044, d5p8bA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 344
1045, d5p83A_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 336
1046, d5p73A_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 300
1047, d5p6dA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 274
1048, d5p6aA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 271
1049, d5p5tA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 254
1050, d5p5sA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 253
1051, d5p5pA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 250
1052, d5p53A_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 228
1053, d5p4oA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 213
1054, d5p3zA_, 0.7234, 2.68, 0.228, 323, 311, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 188
1055, d5p3xA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 186
1056, d5p3qA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 179
1057, d5p3hA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 170
1058, d5p3cA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 165
1059, d5p2wA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 149
1060, d5p2tA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 146
1061, d5p2lA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 139
1062, d5p1pA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 108
1063, d5p1mA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 105
1064, d5p1lA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 104
1065, d5p1aA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 93
1066, d5p0xA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 80
1067, d5p0oA_, 0.7234, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 71
1068, d5mb7A_, 0.7234, 2.83, 0.239, 330, 314, COCKTAIL EXPERIMENT B: FRAGMENTS 224 AND 236 AT 50MM CONCENTRATION
1069, d5lwrA_, 0.7234, 2.86, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH A DERIVATIVE OF FRAGMENT 177
1070, d5dr0A_, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 203
1071, d5dq1A_, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 34
1072, d4y5lA_, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN ITS APO FORM
1073, d4y5gA_, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 272
1074, d4y4aA_, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 286
1075, d4y3yA_, 0.7234, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B42
1076, d4aa9A_, 0.7234, 2.83, 0.239, 330, 314, CAMEL CHYMOSIN AT 1.6A RESOLUTION
1077, d5p8vA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 364
1078, d5p8sA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 361
1079, d5p8nA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 356
1080, d5p8mA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 355
1081, d5p89A_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 342
1082, d5p86A_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 339
1083, d5p7yA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 331
1084, d5p7vA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 328
1085, d5p7oA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 321
1086, d5p7kA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 317
1087, d5p7gA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 313
1088, d5p78A_, 0.7233, 2.27, 0.273, 313, 304, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 305
1089, d5p70A_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 297
1090, d5p6zA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 296
1091, d5p6rA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 288
1092, d5p6lA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 282
1093, d5p6hA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 278
1094, d5p6bA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 272
1095, d5p69A_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 270
1096, d5p5zA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 260
1097, d5p5iA_, 0.7233, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 243
1098, d5p5hA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 242
1099, d5p57A_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 232
1100, d5p54A_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 229
1101, d5p4yA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 223
1102, d5p4xA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 222
1103, d5p4sA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 217
1104, d5p4mA_, 0.7233, 2.86, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 211
1105, d5p4kA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 209
1106, d5p44A_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 193
1107, d5p3vA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 184
1108, d5p3oA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 177
1109, d5p2uA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 147
1110, d5p2mA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 140
1111, d5p2kA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 138
1112, d5p1yA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 117
1113, d5p1xA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 116
1114, d5p1iA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 101
1115, d5p1dA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 96
1116, d5p1bA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 94
1117, d5p17A_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 90
1118, d5p0uA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 77
1119, d5p0tA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 76
1120, d5p0rA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 74
1121, d5p0mA_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 69
1122, d5p06A_, 0.7233, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 53
1123, d5ozkA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 31
1124, d5ozjA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 30
1125, d5oyuA_, 0.7233, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 5
1126, d5dq5A_, 0.7233, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 209
1127, d5dpzA_, 0.7233, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 31
1128, d4yckA_, 0.7233, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 211
1129, d4y5mA_, 0.7233, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 328
1130, d4y37A_, 0.7233, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGEMENT 305
1131, d3pmyA_, 0.7233, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1132, d5p8tA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 362
1133, d5p8rA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 360
1134, d5p8pA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 358
1135, d5p8jA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 352
1136, d5p8gA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 349
1137, d5p8dA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 346
1138, d5p88A_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 341
1139, d5p84A_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 337
1140, d5p7pA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 322
1141, d5p7lA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 318
1142, d5p7iA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 315
1143, d5p74A_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 301
1144, d5p6yA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 295
1145, d5p6tA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 290
1146, d5p6mA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 283
1147, d5p5vA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 256
1148, d5p5nA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 248
1149, d5p56A_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 231
1150, d5p4jA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 208
1151, d5p2sA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 145
1152, d5p2rA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 144
1153, d5p1nA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 106
1154, d5p1jA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 102
1155, d5p1hA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 100
1156, d5p15A_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 88
1157, d5p0zA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 82
1158, d5p0yA_, 0.7232, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 81
1159, d5p0wA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 79
1160, d5p0pA_, 0.7232, 2.87, 0.238, 330, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 72
1161, d5p0fA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 62
1162, d5ozbA_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 22
1163, d5oz6A_, 0.7232, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 17
1164, d5isjA_, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH CHIRAL CHLORINATED PRIMARY AMINE FRAGMENT
1165, d5dr4A_, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 231
1166, d5dr1A_, 0.7232, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 278
1167, d4ze6A_, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B39
1168, d4y5nA_, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 337
1169, d4y3eA_, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 5
1170, d3pi0A_, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1171, d3pgiA_, 0.7232, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1172, d5p8qA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 359
1173, d5p8lA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 354
1174, d5p81A_, 0.7231, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 334
1175, d5p7zA_, 0.7231, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 332
1176, d5p7wA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 329
1177, d5p7tA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 326
1178, d5p7mA_, 0.7231, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 319
1179, d5p7hA_, 0.7231, 2.86, 0.241, 329, 315, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 314
1180, d5p7fA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 312
1181, d5p7eA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 311
1182, d5p7dA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 310
1183, d5p7aA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 307
1184, d5p6oA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 285
1185, d5p4qA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 215
1186, d5p4iA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 207
1187, d5p3fA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 168
1188, d5p38A_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 161
1189, d5p35A_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 158
1190, d5p24A_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 122
1191, d5p1wA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 115
1192, d5p1uA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 113
1193, d5p1gA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 99
1194, d5p0iA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 65
1195, d5p05A_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 52
1196, d5ozsA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 39
1197, d5ozdA_, 0.7231, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 24
1198, d5lwuA_, 0.7231, 2.84, 0.239, 330, 314, STRUCTURE RESULTING FROM AN ENDOTHIAPEPSIN CRYSTAL SOAKED WITH A DIMERIC DERIVATIVE OF FRAGMENT 177
1199, d5lwtA_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A METHOXYLATED DERIVATIVE OF FRAGMENT 177
1200, d5j25A_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158
1201, d5dr7A_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 311
1202, d4yd7A_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 255
1203, d4y51A_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 52
1204, d4y50A_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 81
1205, d4y3tA_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 207
1206, d4y3pA_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 17
1207, d4y3gA_, 0.7231, 2.83, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 285
1208, d4y35A_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 290
1209, d3t7qA_, 0.7231, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1210, d5p8kA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 353
1211, d5p8iA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 351
1212, d5p8aA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 343
1213, d5p7xA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 330
1214, d5p7bA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 308
1215, d5p79A_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 306
1216, d5p52A_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 227
1217, d5p4hA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 206
1218, d5p2cA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 130
1219, d5p1tA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 112
1220, d5p18A_, 0.7230, 2.83, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 91
1221, d5p16A_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 89
1222, d5p08A_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 55
1223, d5ozxA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 44
1224, d5ozfA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 26
1225, d5ozeA_, 0.7230, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 25
1226, d5dr8A_, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 330
1227, d4yd4A_, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 227
1228, d4y5aA_, 0.7230, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 206
1229, d4y41A_, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 112
1230, d4y3wA_, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 35
1231, d4lapA_, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP114
1232, d4l6bA_, 0.7230, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP128
1233, d5p5fA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 240
1234, d5p4gA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 205
1235, d5p14A_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 87
1236, d5p13A_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 86
1237, d5p12A_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 85
1238, d5p11A_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 84
1239, d5p10A_, 0.7229, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 83
1240, d5p0jA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 66
1241, d5p0gA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 63
1242, d5p0dA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 60
1243, d5p0aA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 57
1244, d5ozzA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 46
1245, d5ozrA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 38
1246, d5ozpA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 36
1247, d5ozoA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 35
1248, d5oziA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 29
1249, d5ozhA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 28
1250, d5ozgA_, 0.7229, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 27
1251, d5lwsA_, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 177 AND A DERIVATIVE THEREOF
1252, d5dq4A_, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 66
1253, d4yd6A_, 0.7229, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 240
1254, d4y57A_, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 63
1255, d4y3lA_, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 205
1256, d3t7xA_, 0.7229, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1257, d3lzyA_, 0.7229, 2.85, 0.239, 330, 314, CRYSTAL STRUCTURE OF ENDOTHIAPESIN IN COMPLEX WITH XENON
1258, d5p8cA_, 0.7228, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 345
1259, d5p87A_, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 340
1260, d5p7nA_, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 320
1261, d5p5uA_, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 255
1262, d5p27A_, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 125
1263, d5p22A_, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 120
1264, d5p0vA_, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 78
1265, d5p0lA_, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 68
1266, d5oztA_, 0.7228, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 40
1267, d5ozcA_, 0.7228, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 23
1268, d5oz0A_, 0.7228, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 11
1269, d5iskA_, 0.7228, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FLUORINATED PRIMARY AMINE FRAGMENT
1270, d4y56A_, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 58
1271, d4y54A_, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 56
1272, d4y53A_, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 54
1273, d4y4wA_, 0.7228, 2.87, 0.238, 330, 315, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 125
1274, d3pldA_, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1275, d3pb5A_, 0.7228, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1276, d5p0bA_, 0.7227, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 58
1277, d5p09A_, 0.7227, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 56
1278, d4y3fA_, 0.7227, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 78
1279, d3t7pA_, 0.7227, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A HYDRAZIDE DERIVATIVE
1280, d5p85A_, 0.7226, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 338
1281, d5p6uA_, 0.7226, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 291
1282, d5p07A_, 0.7226, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 54
1283, d5ozwA_, 0.7226, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 43
1284, d4zeaA_, 0.7226, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B91
1285, d4y5pA_, 0.7226, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 338
1286, d4y47A_, 0.7226, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 162
1287, d4y45A_, 0.7226, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 291
1288, d4y3xA_, 0.7226, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 171
1289, d3pllA_, 0.7226, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1290, d3pbdA_, 0.7226, 2.84, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1291, d3fv3D_, 0.7226, 2.85, 0.239, 330, 314, SECRETED ASPARTIC PROTEASE 1 FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH PEPSTATIN A
1292, d2v00A_, 0.7226, 2.84, 0.239, 330, 314, X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1
1293, d5p3iA_, 0.7225, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 171
1294, d5ozmA_, 0.7225, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 33
1295, d5ozaA_, 0.7225, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 21
1296, d5mb0A_, 0.7225, 2.87, 0.241, 328, 315, COCKTAIL EXPERIMENT A: FRAGMENTS 63 267 AND 291 IN COMPLEX WITH ENDOTHIAPEPSIN
1297, d5p4rA_, 0.7224, 2.84, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 216
1298, d5p0kA_, 0.7224, 2.79, 0.240, 329, 313, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 67
1299, d5p04A_, 0.7224, 2.85, 0.239, 330, 314, AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 51
1300, d4y4xA_, 0.7224, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 51
1301, d4rldB1, 0.7224, 2.85, 0.239, 330, 314, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1302, d3pcwA_, 0.7224, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT
1303, d1od1A_, 0.7224, 2.61, 0.214, 338, 308, ENDOTHIAPEPSIN PD135040 COMPLEX
1304, d3t6iA_, 0.7223, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN AZEPIN DERIVATIVE
1305, d3pwwA_, 0.7223, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH SAQUINAVIR
1306, d3psyA_, 0.7223, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION
1307, d3wz6A_, 0.7220, 2.86, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (5)
1308, d1izeA_, 0.7220, 2.85, 0.239, 330, 314, CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE COMPLEXED WITH PEPSTATIN
1309, d1eagA_, 0.7220, 2.85, 0.239, 330, 314, SECRETED ASPARTIC PROTEINASE (SAP2) FROM CANDIDA ALBICANS COMPLEXED WITH A70450
1310, d3pczA_, 0.7216, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH BENZAMIDINE
1311, d2h6sA_, 0.7214, 2.85, 0.239, 330, 314, SECRETED ASPARTIC PROTEINASE (SAP) 3 FROM CANDIDA ALBICANS
1312, d3lizA1, 0.7211, 2.85, 0.239, 330, 314, CRYSTAL STRUCTURE OF BLA G 2 COMPLEXED WITH FAB 4C3
1313, d2nr6B1, 0.7210, 2.73, 0.158, 326, 311, CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
1314, d4y58A_, 0.7209, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 260
1315, d1yg9A1, 0.7207, 2.85, 0.239, 330, 314, THE STRUCTURE OF MUTANT (N93Q) OF BLA G 2
1316, d1tzsA_, 0.7207, 2.85, 0.239, 330, 314, CRYSTAL STRUCTURE OF AN ACTIVATION INTERMEDIATE OF CATHEPSIN E
1317, d4y3rA_, 0.7206, 2.85, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 306
1318, d2nr6A1, 0.7206, 2.85, 0.239, 330, 314, CRYSTAL STRUCTURE OF THE COMPLEX OF ANTIBODY AND THE ALLERGEN BLA G 2
1319, d3vcmB_, 0.7204, 2.86, 0.239, 330, 314, CRYSTAL STRUCTURE OF HUMAN PRORENIN
1320, d4rldA1, 0.7201, 2.69, 0.226, 323, 310, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1321, d4rldC1, 0.7197, 2.74, 0.233, 339, 309, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1322, d4yctA_, 0.7192, 2.87, 0.239, 330, 314, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 216
1323, d4ybfA_, 0.7187, 2.87, 0.217, 340, 313, ASPARTIC PROTEINASE SAPP2 SECRETED FROM CANDIDA PARAPSILOSIS AT 1.25 A RESOLUTION
1324, d4rldD1, 0.7185, 2.74, 0.157, 327, 312, CRYSTAL STRUCTURE OF KKF MUTANT OF BLA G 2 PROTEIN
1325, d2qzwB_, 0.7175, 2.74, 0.157, 327, 312, SECRETED ASPARTIC PROTEINASE (SAP) 1 FROM CANDIDA ALBICANS
1326, d3q70A_, 0.7172, 2.80, 0.157, 325, 312, SECRETED ASPARTIC PROTEASE IN COMPLEX WITH RITONAVIR
1327, d1ibqB_, 0.7163, 2.83, 0.236, 329, 313, ASPERGILLOPEPSIN FROM ASPERGILLUS PHOENICIS
1328, d3pvkA_, 0.7157, 2.66, 0.158, 325, 310, SECRETED ASPARTIC PROTEASE 2 IN COMPLEX WITH BENZAMIDINE
1329, d3vlaA_, 0.7129, 2.43, 0.262, 322, 305, CRYSTAL STRUCTURE OF EDGP
1330, d3vcmA_, 0.7122, 2.84, 0.240, 329, 313, CRYSTAL STRUCTURE OF HUMAN PRORENIN
1331, d1izdA_, 0.7117, 2.71, 0.158, 325, 311, CRYSTAL STRUCTURE OF ASPERGILLUS ORYZAE ASPARTIC PROTEINASE
1332, d3vlbA_, 0.7113, 2.64, 0.248, 325, 306, CRYSTAL STRUCTURE OF XEG-EDGP
1333, d3vlbC_, 0.7108, 2.71, 0.158, 326, 311, CRYSTAL STRUCTURE OF XEG-EDGP
1334, d4ycyA_, 0.7090, 2.74, 0.158, 326, 311, ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 218
1335, d4pphE_, 0.7080, 2.89, 0.239, 328, 314, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1336, d4pphB_, 0.7077, 2.82, 0.222, 334, 311, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1337, d4pphF_, 0.7064, 2.73, 0.158, 326, 310, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1338, d3aupB_, 0.7062, 3.06, 0.217, 341, 314, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1339, d4pphD_, 0.7061, 2.73, 0.235, 334, 307, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1340, d4pphC_, 0.7044, 2.90, 0.230, 325, 313, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1341, d5bwyA_, 0.7042, 2.54, 0.230, 330, 304, STRUCTURE OF PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM SPACE GROUP P43212
1342, d4pphA_, 0.7024, 3.62, 0.168, 412, 327, CRYSTAL STRUCTURE OF CONGLUTIN GAMMA A UNIQUE BASIC 7S GLOBULIN FROM LUPINE SEEDS
1343, d1t6gB_, 0.7024, 3.62, 0.168, 412, 327, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
1344, d1t6gA_, 0.7018, 2.80, 0.252, 335, 306, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-I IN COMPLEX WITH ASPERGILLUS NIGER XYLANASE-I
1345, d3aupC_, 0.7013, 2.88, 0.226, 323, 310, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1346, d1t6eX_, 0.6998, 3.60, 0.153, 404, 326, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR I
1347, d3aupA_, 0.6980, 3.65, 0.153, 403, 327, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1348, d3qvcA_, 0.6957, 2.84, 0.240, 323, 308, CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) ZYMOGEN FROM PLASMODIUM FALCIPARUM
1349, d3hd8A_, 0.6940, 3.40, 0.172, 391, 319, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1350, d2b42A1, 0.6937, 3.45, 0.169, 391, 320, CRYSTAL STRUCTURE OF THE TRITICUM XYLANSE INHIBITOR-I IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1351, d1miqB_, 0.6916, 3.39, 0.172, 392, 319, CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1352, d1miqA_, 0.6916, 3.31, 0.148, 372, 318, CRYSTAL STRUCTURE OF PROPLASMEPSIN FROM THE HUMAN MALARIAL PATHOGEN PLASMODIUM VIVAX
1353, d1pfzA_, 0.6906, 3.44, 0.172, 392, 319, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1354, d1pfzB_, 0.6899, 3.39, 0.173, 392, 318, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1355, d3hd8C_, 0.6897, 3.39, 0.173, 392, 318, CRYSTAL STRUCTURE OF THE TRITICUM AESTIVUM XYLANASE INHIBITOR-IIA IN COMPLEX WITH BACILLUS SUBTILIS XYLANASE
1356, d1pfzD_, 0.6887, 3.25, 0.226, 376, 318, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1357, d3aupD_, 0.6868, 3.25, 0.226, 376, 318, CRYSTAL STRUCTURE OF BASIC 7S GLOBULIN FROM SOYBEAN
1358, d1pfzC_, 0.6844, 3.39, 0.170, 390, 317, PROPLASMEPSIN II FROM PLASMODIUM FALCIPARUM
1359, d3q6yA_, 0.6780, 3.18, 0.151, 368, 312, ENDOTHIAPEPSIN IN COMPLEX WITH A PYRROLIDINE BASED INHIBITOR
1360, p4zsrB1, 0.6763, 3.33, 0.143, 368, 314, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
1361, p3lpjB1, 0.6763, 3.43, 0.180, 372, 316, STRUCTURE OF BACE BOUND TO SCH743641
1362, p4zsqB1, 0.6761, 3.34, 0.140, 362, 314, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
1363, p4zsqA1, 0.6760, 3.35, 0.156, 377, 315, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
1364, p3lpkA1, 0.6754, 3.40, 0.223, 368, 318, STRUCTURE OF BACE BOUND TO SCH747123
1365, p3lpjA1, 0.6753, 3.31, 0.148, 370, 311, STRUCTURE OF BACE BOUND TO SCH743641
1366, p3lpiA1, 0.6753, 3.31, 0.148, 370, 311, STRUCTURE OF BACE BOUND TO SCH745132
1367, p6bfxA1, 0.6746, 3.30, 0.145, 364, 310, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1368, p4ybiA1, 0.6742, 3.40, 0.221, 375, 317, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2811376
1369, p6bfxB1, 0.6731, 3.40, 0.222, 373, 315, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1370, p4trwB1, 0.6729, 3.16, 0.225, 370, 311, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
1371, p5he5A1, 0.6698, 3.16, 0.225, 369, 311, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLAMINO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1372, p5hduA1, 0.6698, 3.32, 0.149, 368, 309, BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1373, p5hd0A1, 0.6697, 3.24, 0.225, 369, 311, BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[34- D]PYRIMIDIN-2-IMINIUM
1374, p4trzA1, 0.6670, 3.31, 0.173, 360, 306, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
1375, p4trzC1, 0.6668, 3.32, 0.222, 356, 311, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
1376, p4tryB1, 0.6634, 2.88, 0.244, 305, 295, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
1377, p4tryC1, 0.6590, 0.44, 1.000, 264, 264, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
1378, p4ybiB1, 0.6557, 0.44, 1.000, 264, 264, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2811376
1379, p4fseD1, 0.6533, 0.45, 1.000, 264, 264, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
1380, p4fseB1, 0.6533, 0.46, 1.000, 264, 264, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
1381, p4fseE1, 0.6532, 0.55, 1.000, 265, 264, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
1382, p4fseA1, 0.6532, 0.56, 1.000, 265, 264, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH N-(N-(4-AMINO-35- DICHLOROBENZYL)CARBAMIMIDOYL)-3-(4- METHOXYPHENYL)-5- METHYL-4-ISOTHIAZOLECARBOXAMIDE
1383, p6bfwB1, 0.6528, 0.56, 1.000, 265, 264, BACE CRYSTAL STRUCTURE WITH HYDROXY MORPHOLINE INHIBITOR
1384, p4zsmB1, 0.6527, 0.60, 1.000, 264, 264, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT
1385, p3skfB1, 0.6513, 0.38, 1.000, 263, 263, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE
1386, p3skfA1, 0.6513, 0.48, 1.000, 263, 263, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE
1387, p4trwA1, 0.6501, 0.98, 1.000, 267, 266, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
1388, p3r2fD1, 0.6498, 0.30, 1.000, 262, 261, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
1389, p3r2fE1, 0.6497, 0.30, 1.000, 262, 261, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
1390, p3r2fB1, 0.6496, 0.31, 1.000, 262, 261, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
1391, p3r2fA1, 0.6496, 0.71, 1.000, 263, 262, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH BMS-693391 AKA (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1- PYRROLIDINYL)-N-((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-((2R4R)- 4-PROPOXY-2-PYRROLIDINYL)ETHYL)-4-PHENYLBUTANAMIDE
1392, p3skgB1, 0.6490, 0.75, 1.000, 263, 262, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
1393, p3skgA1, 0.6489, 0.92, 1.000, 263, 262, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
1394, p3skgD1, 0.6488, 1.11, 0.985, 263, 261, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
1395, p3skgE1, 0.6485, 0.43, 1.000, 256, 256, CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3R)-3-ACETAMIDO-3-ISOBUTYL-2-OXO-1-PYRROLIDINYL)-N- ((1S2R)-1-(35-DIFLUOROBENZYL)-2-HYDROXY-2-(1234-TETRAHYDRO-3- ISOQUINOLINYL)ETHYL)-4-PHENYLBUTANAMIDE
1396, p4trzB1, 0.6459, 0.43, 1.000, 255, 255, STRUCTURE OF BACE1 COMPLEX WITH 2-THIOPHENYL HEA-TYPE INHIBITOR
1397, p5v0nC1, 0.6320, 0.43, 1.000, 255, 255, BACE1 IN COMPLEX WITH INHIBITOR 5G
1398, p4jooA1, 0.6198, 0.43, 1.000, 255, 255, SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS
1399, p3uqrA1, 0.6128, 0.44, 1.000, 255, 255, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1400, p6ej3A1, 0.5977, 0.48, 1.000, 255, 255, BACE1 COMPOUND 23 
1401, p3zl7A1, 0.5812, 0.48, 1.000, 255, 255, BACE2 FYNOMER COMPLEX
1402, p4ehcA_, 0.5624, 0.61, 1.000, 255, 255, CRYSTAL STRUCTURE OF THE C-TERMINAL DOMAIN OF RV0977 OF MYCOBACTERIUM TUBERCULOSIS
1403, p4zspB2, 0.5200, 0.62, 1.000, 255, 255, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE INHIBITOR
1404, p5hu0A2, 0.5199, 0.86, 1.000, 257, 256, BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5- OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM
1405, p6bfeA2, 0.5198, 0.52, 1.000, 254, 254, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1406, p5hu0B2, 0.5198, 0.53, 1.000, 254, 254, BACE1 IN COMPLEX WITH 4-(3-(FURAN-2-CARBOXAMIDO)PHENYL)-1-METHYL-5- OXO-4-PHENYLIMIDAZOLIDIN-2-IMINIUM
1407, p3lpkB2, 0.5198, 0.53, 1.000, 254, 254, STRUCTURE OF BACE BOUND TO SCH747123
1408, p6bfeB2, 0.5197, 0.53, 1.000, 254, 254, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1409, p6bfdB2, 0.5197, 0.58, 1.000, 254, 254, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1410, p4zsrA2, 0.5197, 0.58, 1.000, 254, 254, BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR
1411, p4zspA2, 0.5197, 0.59, 1.000, 254, 254, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE INHIBITOR
1412, p3lpiB2, 0.5197, 0.62, 1.000, 254, 254, STRUCTURE OF BACE BOUND TO SCH745132
1413, p4zsmA2, 0.5196, 0.90, 1.000, 256, 255, BACE CRYSTAL STRUCTURE WITH BICYCLIC AMINOTHIAZINE FRAGMENT
1414, p5mxdC2, 0.5189, 1.23, 0.992, 252, 251, BACE-1 IN COMPLEX WITH LIGAND 32397778
1415, p5mxdA2, 0.5188, 1.35, 0.972, 252, 247, BACE-1 IN COMPLEX WITH LIGAND 32397778
1416, p5mbwA2, 0.5187, 0.86, 0.992, 242, 241, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH PEP#3
1417, p4trwC2, 0.5182, 0.64, 1.000, 236, 234, STRUCTURE OF BACE1 COMPLEX WITH A SYN-HEA-TYPE INHIBITOR
1418, p5htzB2, 0.5178, 1.86, 0.544, 238, 237, BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3- YL)THIOPHEN-2-YL)-25-DIMETHYL-124-THIADIAZINAN-3-IMINIUM 11- DIOXIDE
1419, p6dhcB2, 0.5172, 3.41, 0.133, 275, 256, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
1420, p6bfwA2, 0.5171, 3.41, 0.133, 275, 256, BACE CRYSTAL STRUCTURE WITH HYDROXY MORPHOLINE INHIBITOR
1421, p6bfdA2, 0.5171, 0.43, 1.000, 203, 203, BACE CRYSTAL STRUCTURE WITH HYDROXY PYRROLIDINE INHIBITOR
1422, p4tryA2, 0.5170, 0.45, 1.000, 204, 203, STRUCTURE OF BACE1 COMPLEX WITH A HEA-TYPE INHIBITOR
1423, p6c2iA2, 0.5169, 0.47, 1.000, 203, 203, STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH : N-(3-((1R5S 6R)-3-AMINO-5-METHYL-2-OXA-4-AZABICYCLO[4.1.0]HEPT-3-EN-5-YL)-4- FLUOROPHENYL)-5-METHOXYPYRAZINE-2-CARBOXAMIDE
1424, p6dhcA2, 0.5167, 0.46, 1.000, 203, 203, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
1425, p5mcqA2, 0.5154, 0.46, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE AND EXOSITE BINDING PEPTIDE INHIBITOR
1426, p4x7iB2, 0.5150, 0.48, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2886721
1427, p4x7iA2, 0.5149, 0.48, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE WITH AMINO THIAZINE INHIBITOR LY2886721
1428, p3tplB2, 0.5145, 0.47, 1.000, 203, 203, APO STRUCTURE OF BACE1
1429, p4dv9A2, 0.5142, 0.47, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1430, p4dvfB2, 0.5140, 0.47, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1431, p5hdvA2, 0.5133, 0.49, 1.000, 203, 203, BACE-1 INCOMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1432, p5ygyA2, 0.5132, 0.58, 1.000, 203, 203, CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH (S)-N-(3-(2-AMINO-6- (FLUOROMETHYL)-4 -METHYL-4H-1;3-OXAZIN-4-YL)-4-FLUOROPHENYL)-5- CYANOPICOLINAMIDE 
1433, p5hdxB2, 0.5132, 0.58, 1.000, 203, 203, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(4-ETHOXY-5- FLUORO-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1434, p5hdxA2, 0.5132, 0.58, 1.000, 204, 203, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(4-ETHOXY-5- FLUORO-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1435, p5hu1A2, 0.5131, 0.61, 1.000, 204, 203, BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-25-DIMETHYL-11-DIOXIDO-56- DIHYDRO-2H-124-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5- FLUOROPICOLINAMIDE
1436, p5htzA2, 0.5131, 0.38, 1.000, 202, 202, BACE1 IN COMPLEX WITH (S)-5-(3-CHLORO-5-(5-(PROP-1-YN-1-YL)PYRIDIN-3- YL)THIOPHEN-2-YL)-25-DIMETHYL-124-THIADIAZINAN-3-IMINIUM 11- DIOXIDE
1437, p5he7B2, 0.5131, 0.74, 1.000, 204, 203, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(24-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-2-IMINO-3-METHYLOCTAHYDRO-4H- PYRROLO[34-D]PYRIMIDIN-4-ONE
1438, p5he7A2, 0.5131, 0.48, 1.000, 202, 202, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(24-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-2-IMINO-3-METHYLOCTAHYDRO-4H- PYRROLO[34-D]PYRIMIDIN-4-ONE
1439, p5he5B2, 0.5131, 0.48, 1.000, 202, 202, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLAMINO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1440, p5he4A2, 0.5131, 0.71, 1.000, 203, 203, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(26-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1441, p5hdzB2, 0.5131, 0.79, 0.975, 205, 203, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLTHIO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1442, p5hdzA2, 0.5131, 0.74, 1.000, 203, 203, BACE-1 IN COMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHYL-6-(METHYLTHIO)PYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1443, p5hdvB2, 0.5131, 0.94, 1.000, 205, 203, BACE-1 INCOMPLEX WITH (7AR)-7A-(5-CYANOTHIOPHEN-2-YL)-6-(5-FLUORO-4- METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1444, p5hduB2, 0.5131, 0.70, 1.000, 202, 202, BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3 4-D]PYRIMIDIN-2-IMINIUM
1445, p5hd0B2, 0.5131, 0.72, 1.000, 202, 202, BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[34- D]PYRIMIDIN-2-IMINIUM
1446, p5hu1B2, 0.5130, 0.48, 0.990, 202, 201, BACE1 IN COMPLEX WITH (R)-N-(3-(3-AMINO-25-DIMETHYL-11-DIOXIDO-56- DIHYDRO-2H-124-THIADIAZIN-5-YL)-4-FLUOROPHENYL)-5- FLUOROPICOLINAMIDE
1447, p5he4B2, 0.5130, 1.13, 1.000, 203, 203, BACE-1 IN COMPLEX WITH (4AR7AS)-7A-(26-DIFLUOROPHENYL)-6-(5-FLUORO- 4-METHOXY-6-METHYLPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H- PYRROLO[34-D]PYRIMIDIN-2-IMINIUM
1448, p5mcoA2, 0.5121, 0.53, 1.000, 202, 201, CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH ACTIVE SITE INHIBITOR GRL- 8234 AND EXOSITE PEPTIDE
1449, p6dhcC2, 0.5115, 0.29, 1.000, 201, 200, X-RAY STRUCTURE OF BACE1 IN COMPLEX WITH A BICYCLIC ISOXAZOLINE CARBOXAMIDE AS THE P3 LIGAND 
1450, p6fgyA2, 0.5111, 0.86, 0.975, 203, 202, CRYSTAL STRUCTURE OF HUMAN BACE-1 IN COMPLEX WITH AMINO-1;4-OXAZINE COMPOUND 4 
1451, p3uqrC2, 0.5106, 0.31, 1.000, 200, 200, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1452, p6ej2A2, 0.5103, 0.30, 1.000, 201, 200, BACE1 COMPOUND 28 
1453, p3tplC2, 0.5100, 0.32, 1.000, 201, 200, APO STRUCTURE OF BACE1
1454, p4dvfA2, 0.5094, 0.31, 1.000, 201, 200, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1455, p4fgxA2, 0.5089, 0.32, 1.000, 200, 200, CRYSTAL STRUCTURE OF BACE1 WITH NOVEL INHIBITOR
1456, p3uqrB2, 0.5065, 0.31, 1.000, 201, 200, CRYSTAL STRUCTURE OF BACE1 WITH ITS INHIBITOR
1457, p5mxdB2, 0.5055, 0.31, 1.000, 200, 200, BACE-1 IN COMPLEX WITH LIGAND 32397778
1458, p5dqcC2, 0.5047, 0.31, 1.000, 201, 200, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
1459, p5dqcA2, 0.5030, 0.32, 1.000, 200, 200, CO-CRYSTAL OF BACE1 WITH COMPOUND 0211
